

CD206⁺IL-4R α ⁺ MACROPHAGES ARE DRIVERS OF ADVERSE CARDIAC REMODELING IN ISCHEMIC CARDIOMYOPATHY

Qiongxin Wang, PhD;^{1,2,3} Mohamed Ameen Ismahil, PhD;^{1,3} Yujie Zhu, MD, PhD;^{1,3} Gregg Rokosh, PhD;^{1,3} Tariq Hamid, PhD;^{1,3} Guihua Zhou, MD, PhD;¹ Steven M. Pogwizd, MD;¹ Sumanth D. Prabhu, MD^{1,3}

¹Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL

²Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China,

³Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO

Running title: Alternatively activated macrophages promote adverse cardiac remodeling

Corresponding Author:

Sumanth D. Prabhu, MD
Lewin Distinguished Professor and Chief
Division of Cardiology
Washington University School of Medicine
660 S. Euclid Ave
CB 8086
St. Louis, MO 63110
Tel: 314-362-8908
Fax: 314-454-5550
Email: prabhu@wustl.edu

NONSTANDARD ABBREVIATIONS AND ACRONYMS

| | |
|--------------------------------|--------------------------------|
| LV | left ventricular |
| MI | myocardial infarction |
| HF | heart failure |
| EF | ejection fraction |
| EDV | end-diastolic volume |
| ESV | end-systolic volume |
| LVAD | left ventricular assist device |
| BMDM | bone marrow-derived macrophage |
| cMSC | cardiac mesenchymal stem cell |
| ASO | antisense oligonucleotide |
| CCR2 | C-C motif chemokine receptor 2 |
| IL | interleukin |
| TGF-β | tumor growth factor- β |
| Arg1 | arginase 1 |
| FIZZ | found in inflammatory zone |
| Col | collagen |
| PDGF | platelet-derived growth factor |
| α-SMA | α -smooth muscle actin |
| NICD | Notch intracellular domain |

1 **ABSTRACT**

2 **BACKGROUND:** Cardiac CD206⁺ macrophages expand acutely after myocardial infarction (MI)
3 to promote wound healing; however, their role in chronic heart failure (HF) is unknown. We
4 tested the hypothesis that cardiac CD206⁺ macrophages expressing interleukin(IL)-4R α are key
5 drivers of adverse left ventricular (LV) remodeling in HF.

6 **METHODS AND RESULTS:** Adult male C57BL/6 mice underwent non-reperfused MI to induce
7 HF, or sham operation, and cardiac macrophages were profiled using flow cytometry. As
8 compared to sham, CD206⁺ macrophages steadily expanded in post-MI hearts during LV
9 remodeling, such that at 8 w post-MI they comprised ~85% of all macrophages. These
10 macrophages were robustly proliferative and predominantly C-C motif chemokine receptor
11 (CCR2)⁻ and major histocompatibility complex (MHC)II^{hi}, with >90% of CD206⁺CCR2⁻
12 macrophages expressing the resident macrophage marker LYVE-1. CD206⁺ macrophage
13 abundance correlated with LV dysfunction and fibrosis. Nearly half of CD206⁺ macrophages
14 expressed IL-4R α , and the majority of CD206⁺IL-4R α ⁺ macrophages co-expressed the pro-
15 fibrotic protein found in inflammatory zone (FIZZ)1. IL-4-polarized bone marrow derived CD206⁺
16 macrophages also exhibited marked upregulation of FIZZ1 and induced FIZZ1-dependent
17 myofibroblast differentiation of cardiac mesenchymal stem cells (cMSCs), in part related to DLL-
18 4/Jagged1-Notch1 signaling. Intramyocardial adoptive transfer of M[IL-4], but not M[IL-10],
19 CD206⁺ macrophages to naïve mice, induced progressive LV remodeling over 4 weeks,
20 increasing fibrosis, cardiomyocyte hypertrophy, and apoptosis. Myeloid-specific IL-4R α gene
21 deletion in established HF (initiated 4 w post-MI) in IL-4R α ^{fl/fl}LysM-Cre^{ERT2} mice significantly
22 reduced CD206⁺ macrophage proliferation and effectively depleted CD206⁺IL-4R α ⁺ cardiac
23 macrophages. This was associated with abrogation of LV remodeling progression, reduction of
24 cardiac fibrosis, and improved neovascularization. *In vivo* IL-4R α gene silencing in mice with
25 established HF effectively depleted cardiac CD206⁺IL-4R α ⁺ macrophages and reversed LV

26 remodeling, improving fibrosis, neovascularization, and dysfunction, and suppressed both local
27 and systemic inflammation. Lastly, alternatively activated CD206⁺ and CD163⁺ macrophages
28 were significantly expanded in human failing hearts and correlated with fibrosis. The majority of
29 CD163⁺ macrophages expressed IL-4R α and FIZZ3, the human homolog of FIZZ1.

30 **CONCLUSION:** Cardiac CD206⁺IL-4R α ⁺ macrophages proliferate and expand in HF and are
31 key mediators of pathological remodeling and fibrosis, in part through the secretion of FIZZ1.
32 Inhibition of CD206⁺ macrophage IL-4R α signaling alleviates LV remodeling in ischemic
33 cardiomyopathy.

34

35 **Key Words:** CD206⁺ macrophages; fibrosis; heart failure; interleukin 4 receptor- α ; inflammation

36 **CLINICAL PERSPECTIVE**

37

38 *What is new?*

- 39 • In the failing heart after myocardial infarction (MI), CD206⁺ macrophages, primarily CCR2⁻,
40 MHCII^{hi}, and LYVE1⁺, robustly proliferate with a subpopulation expressing IL-4R α ;
41 myeloid-specific IL-4R α deletion or IL-4R α silencing *in vivo* tempered CD206⁺
42 macrophage proliferation and alleviated LV dysfunction, fibrosis, and remodeling.
- 43 • M[IL-4] CD206⁺ bone-marrow derived macrophages induced upregulation of *Fizz1*, and
44 FIZZ1-dependent cardiac mesenchymal myofibroblast differentiation; intramyocardial
45 adoptive transfer of M[IL-4] macrophages induced cardiac remodeling and fibrosis.
- 46 • Humans exhibit expansion of alternatively activated macrophages in the failing heart
47 marked by CD206 and CD163 expression, with predominance of a subpopulation
48 expressing IL-4R α and Fizz3, the human homolog of *Fizz1*.

49 *What are the clinical implications?*

- 50 • An expanded pool of alternatively activated CD206⁺IL-4R α ⁺ cardiac macrophages are key
51 drivers of LV remodeling in heart failure, inducing an immuno-fibrotic and para-
52 inflammatory response in part dependent on FIZZ1.
- 53 • Targeting IL-4 signaling in CD206⁺ macrophages represents a potential therapeutic
54 approach to limit long-term cardiac remodeling in heart failure.

55 INTRODUCTION

56 Heart failure (HF) is characterized by local and systemic inflammation.¹ In ischemic
57 cardiomyopathy, activated macrophages expand in the failing myocardium and contribute to
58 tissue injury and adverse left ventricular (LV) remodeling.¹⁻⁵ Cardiac macrophages may be
59 classified as C-C motif chemokine receptor (CCR2)⁻ resident macrophages that are
60 embryonically derived and maintained independent of blood monocytes, and CCR2⁺
61 macrophages that are derived from monocyte recruitment.⁶⁻⁸ Acutely after myocardial infarction
62 (MI), resident CCR2⁻ macrophages are lost and replaced by Ly6C^{hi}CCR2⁺ monocytes and
63 inflammatory CCR2⁺ macrophages that later transition to reparative macrophages to facilitate
64 wound healing, accompanied by attendant proliferation of surviving resident macrophage
65 populations.^{3,6,9-11} Notably, in chronic ischemic cardiomyopathy, well after MI healing, the
66 expanded cardiac macrophage pool stems from both locally proliferating resident macrophages
67 and recruited CCR2⁺ monocytes,^{2,3,5,6,12} with overall predominance of locally sourced (CCR2⁻)
68 cells.^{3,5,12} CCR2⁺ macrophage abundance correlates with adverse LV remodeling in human
69 HF,² whereas inhibiting CCR2⁺ monocyte infiltration sub-acutely after MI improves LV
70 remodeling in mice,⁵ identifying CCR2 as a potential therapeutic target. In contrast, the roles of
71 locally sourced macrophage populations in the pathogenesis of LV remodeling in established
72 HF are poorly defined.

73 Resident cardiac macrophages express several marker genes including *Timd4*, *Lyve1*,
74 and classical alternatively-activated (M2-like) macrophage markers *Cd163* and *Mrc1*.^{2,6,13,14} In
75 the naïve mouse heart, CD206 (*Mrc1*)-expressing resident macrophages are primarily CCR2⁻
76 and express high levels of the markers *Ym1* and *Fizz1*.¹⁵ After acute MI, CD206⁺ macrophages
77 expand in the infarct and border zone (peaking at 7 d post-MI)^{15,16} to promote wound healing
78 and limit adverse remodeling.^{15,17} CD206⁺ macrophages are activated by Th2 cytokines IL-4/13,
79 and IL-10.¹⁸⁻²⁰ IL-4/13 are important inducers of a reparative and pro-fibrotic phenotype,^{18,19,21}
80 signaling through Type I or II IL-4 receptors containing the common alpha chain IL4R α , resulting

81 in STAT6-mediated activation of *Arg1*, *Mrc1*, *Fizz1* (*Retnla*), *Ym1*, and secretion of C-C motif
82 chemokine ligands (CCL)-17 and -22.^{18,20,22,23} In vivo administration of IL-4 acutely after MI
83 improves wound healing and remodeling via the modulation of CD206⁺ macrophages. However,
84 this beneficial effect is lost when IL-4 is given late after MI.^{15,24}

85 These prior studies highlight CD206⁺ macrophages as key mediators of the post-MI
86 wound healing response. However, the importance of this macrophage population in the
87 chronically failing heart, which exhibits a considerably different immune cell profile,^{1,11} is
88 unknown. In chronic ischemic cardiomyopathy, locally sourced and proliferating cardiac
89 macrophages exhibit much greater *Mrc1* and *Fizz1* expression than monocyte-derived
90 macrophages.⁵ Moreover, in chronic pulmonary and renal disease, persistent M[IL-4/13]
91 activation or M2-like macrophage recruitment can contribute to tissue fibrosis,^{21,25} whereas we
92 have previously shown that the post-MI failing heart exhibits increased IL-4/13 expression
93 coincident with a Th2 CD4⁺ T-cell profile.²⁶ Hence, here we tested the hypothesis that
94 expansion of cardiac CD206⁺ macrophages, activated by IL-4 receptor signaling, are key
95 mediators of LV remodeling in chronic ischemic HF.

96 **METHODS**

97 **Mouse models.** All mouse studies complied with the National Research Council's Guide
98 for the Care and Use of Laboratory Animals (revised 2011) and were locally approved by
99 Institutional Animal Care and Use Committees at the University of Alabama at Birmingham and
100 Washington University in St. Louis. CD45.2 (#000664) and CD45.1 (#002014) C57BL/6 mice,
101 *Fizz1*^{-/-} mice (#029976), and LysM-Cre^{ERT2} mice (#031674) were purchased from Jackson
102 Laboratory. Floxed IL4R α (IL4R α ^{ff}) mice²⁷ were originally obtained from Dr. Frank Brombacher
103 (University of Cape Town) and bred with LysM-Cre^{ERT2} mice to generate IL-4R α ^{ff}LysM-Cre^{ERT2}
104 mice that allow for tamoxifen-inducible myeloid-specific deletion of IL-4R α . To induce Cre-
105 mediated recombination, mice were fed tamoxifen citrate chow (40 mg/kg/d; Inotiv TD.130860).

106 As 400mg/kg tamoxifen citrate is sufficient to induce recombination,²⁸ IL-4R α ^{ff}LysM-Cre^{ERT2}
107 mice were considered to reach stable myeloid-specific IL4R α deletion after 2 w of feeding. Male
108 mice were used for experiments unless otherwise indicated. Mice were housed in temperature-
109 controlled cages under a 12-hour light-dark cycle and given free access to water and regular
110 chow. A total of 248 male and 37 female mice at 8-10 weeks of age were used. After terminal
111 experiments, mice were euthanized by isoflurane inhalation (2%).

112 **Murine surgical procedures.** Permanent coronary ligation to induce large MI and
113 ischemic HF, and control sham surgery, were performed under general anesthesia with 1-1.5%
114 inhaled isoflurane and mechanical ventilation as previously described.^{4,26,29-31} For macrophage
115 adoptive transfer, cell suspensions (1×10^6 polarized macrophages in 50 μ L sterile PBS) or
116 sterile PBS control alone were injected intramyocardially into the free wall of left ventricle (10
117 μ L/site x 5 sites) in naïve C57BL/6 male recipient mice.

118 **Echocardiography.** M-mode and 2-dimensional echocardiography were performed
119 under 2% inhaled isoflurane anesthesia (with 98% O₂) and continuous ECG monitoring using a
120 VisualSonics Vevo 3100 High-Resolution System and 30 MHz MX400 transducer with a heated,
121 bench-mounted adjustable rail system.^{4,26,29,32,33} Imaging was performed in the parasternal long-
122 axis and short-axis views. LV chamber volume in end-diastole (EDV) and end-systole (ESV)
123 were quantitated using the area-length method from long-axis images captured in ECG-gated
124 Kilohertz Visualization mode. Systolic function was indexed by LV ejection fraction (EF),
125 calculated as $[(EDV-ESV)/EDV] * 100$. Stroke volume was defined as EDV-ESV. LV mass (mg)
126 was calculated as $1.05 * [(IVSWTd+EDD+PWTd)^3 - (EDD)^3]$, where IVSWTd and PWTd are
127 interventricular septal and LV posterior wall thickness at end-diastole, and EDD is the LV end-
128 diastolic diameter derived from M-mode tracings.

129 **Gene expression analysis.** Total RNA from LV remote zones (≈ 10 mg), macrophages
130 and cMSCs was extracted using Trizol (Invitrogen, 15596026) and Qiagen RNeasy Columns

131 (QIAGEN, 74204)³⁴ and reverse transcribed to cDNA using the High-Capacity cDNA Reverse
132 Transcription Kit (Applied Biosystems, 43-688-14). cDNAs were subjected to qPCR using SYBR
133 Green Master Mix (Applied Biosystems, A25742) and run on a ViiA 7 RT PCR System (Applied
134 Biosystems).^{32,35-37} Forward and reverse primer sequences are listed in *Supplemental Table 1*.

135 **Multiplex Luminex assay.** Peripheral blood was coagulated on ice and centrifuged to
136 separate serum. Cytokine Luminex assay of serum samples was performed in 96-well Bio-Plex
137 Pro Mouse Cytokine microplates and analyzed using the Luminex reader (BIO-RAD, Bio-
138 Plex™ 200 system) according to the manufacturer's protocol.³⁴ Bio-Plex Pro Mouse Cytokine
139 23-plex Assay (M60009RDPD), MIP-2 Set (171G6006M), TGF-β1 Set (171V4001M), Standards
140 Group I (171I50001), Group II Standards (171I60001), TGF-β Standard (171X40001) and
141 Reagent Kit V (12002798) were all purchased from BIO-RAD.

142 **Immunoblot analysis.** Immunoblotting was conducted using standard protocols as
143 described previously,^{33,34,36} using antibodies against mouse Notch1 (Cell Signaling, 4380), NICD
144 (Cell Signaling, 4147) and α-SMA (Abcam, ab7817). GAPDH (Cell Signaling, 97166) and α-
145 tubulin (Santa Cruz, 5286) were used as loading controls.

146 **Immune cell isolation and flow cytometry.** Live mononuclear cells were isolated from
147 peripheral blood and heart tissue and processed for flow cytometry as previously
148 described.^{26,29,38} After 1% paraformaldehyde fixation, isolated cells were resuspended in MACS
149 buffer (PBS with 2 mM EDTA and 0.5% BSA) and preincubated for 10 min at 4°C with anti-
150 mouse CD16/CD32 antibody (eBioscience, #14-0161-82) to block Fcγ receptors.³² Cells were
151 then stained for surface membrane markers upon incubation with fluorophore-labeled anti-
152 mouse CD45, F4/80, MERTK, CD11b, Ly6G, Ly6C, CD3, CD4, CD8, IL-4Rα, IL-10Rα, MHCII,
153 LYVE1, and CCR2, and, for human cardiac mononuclear cells, anti-human CD45, CD64,
154 CD206 and CCR2 for 1 h. Mouse cardiac mononuclear cells were then permeabilized with 0.5%
155 Tween-20 for 20 minutes, followed by staining with anti-mouse CD206 and Ki67 for 1 h. All

156 staining was performed on ice to maintain cell morphology. Flow cytometry was performed
157 using a FACSDiva LSR-II flow cytometer (BD) and analyzed using FlowJo software v10.8.0.
158 Specific details regarding the fluorophore-conjugated antibodies used are listed in *Supplemental*
159 *Table 2*.

160 **(Immuno)histological analysis.** Formalin-fixed, paraffin-embedded heart tissues were
161 sectioned at 5 μm thickness, deparaffinized, and rehydrated. Cardiomyocyte cell membranes
162 and capillaries were stained using Alexa Fluor (AF)555-conjugated wheat-germ agglutinin
163 (Invitrogen, #W32464) and AF488-conjugated isolectin-IB₄ (Invitrogen, #121411),
164 respectively.^{4,26,29,32} After antigen retrieval, LV sections were stained with anti-mouse CD206
165 (1:50, R&D AF2535, secondary anti-goat AF555), Ki67 (1:50, eBioscience 14-5698-82,
166 secondary anti-rat AF488), CD45.2 (1:50, eBioscience 14-0454-82, secondary anti-mouse
167 AF647), α -actinin (1:100, Sigma A2172, secondary anti-mouse AF555), IL-4R α (1:50, Invitrogen
168 PA5-103142, secondary anti-rabbit AFF647) and FIZZ1 (1:50, R&D MAB-1523, secondary anti-
169 rat AF488) or anti-human CD163 (1:100, Leica Biosystems CD163-L-CE, secondary anti-mouse
170 IgG1 AF647), IL-4R α (1:50, R&D MAB230, secondary anti-mouse IgG2a AF488) and FIZZ3
171 (1:50, R&D AF1359, secondary anti-goat AF555) antibodies. After permeabilization with 20
172 $\mu\text{g/ml}$ proteinase K, α -actinin stained LV sections were incubated with TUNEL reaction mix
173 (Biotium 30063) for 2h at 37°C. CD206 or CD163 stained LV sections were incubated with 15
174 μM heat-dissociated collagen hybridizing peptide 5-FAM Conjugate (F-CHP) (3Hekix FLU300)
175 overnight at 4°C. In addition, LV frozen sections (8 μm) were fixed with acetone/chloroform,
176 rehydrated, and stained with anti-mouse F4/80 (1:100, Abcam ab6640, secondary anti-rat
177 AF488) and α -actinin (1:100, Sigma A2172, secondary anti-mouse AF555) antibodies. Nuclei
178 were stained with DAPI. Images were acquired using a Nikon A1 confocal microscope. Fibrosis
179 was measured in LV sections using Masson's Trichrome staining, and images were captured by
180 a Nikon 80i Nomarski DIC microscope. Collagen (blue) staining percent of total cross-sectional

181 area was determined as previously described.^{4,26,29,32} Staining was quantified from more than 5
182 high-power fields (40x) per section using Nikon NIS-Elements software, version 4.60.00.

183 **Bone marrow macrophage culture and adoptive cell transfer.** C57BL/6 (CD45.2) or
184 *Fizz1*^{-/-} mouse bone marrow (BM) cells were harvested aseptically and cultured in RPMI 1640
185 medium, supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (PS) and
186 30 ng/mL recombinant mouse macrophage-colony-stimulating factor (M-CSF, R&D, 416-ML) at
187 37°C. The supernatant was replaced with fresh complete medium containing 30 ng/mL M-CSF
188 every 3 days for the attached cells, following the protocol of Trouplin et al.³⁹ After 7 days of
189 differentiation, BM-derived macrophages (BMDMs) were cultured in RPMI 1640 with 10% FBS
190 and 1% PS for 24 h for M0 (resting) macrophages, with 40 ng/mL recombinant mouse IL-4
191 (R&D, 404-ML) for M[IL-4] macrophages, and with 40 ng/mL recombinant mouse IL-10 (R&D,
192 417-ML) for M[IL-10] macrophages. Polarized macrophages were then mechanically detached,
193 and cell aliquots were stained with anti-mouse CD45, F4/80 and CD206 (*Supplemental Table 2*)
194 and analyzed using a flow cytometer to evaluate macrophage purity. After 24 h of polarization,
195 M0, M[IL-4] and M[IL-10] cells were rinsed with PBS and cultured in FBS-free medium for 3 h.
196 The macrophage conditioned medium was subsequently collected for treatment of cardiac
197 mesenchymal stem cells and fibroblasts, as described below. The polarized macrophages were
198 used for studies of intramyocardial adoptive cell transfer into naïve male CD45.1 C57BL/6 mice
199 as described above.

200 ***In vivo* antisense oligonucleotide administration.** Second-generation chimeric 20-
201 base IL-4R α antisense oligonucleotides (ASOs) (CCGCTGTTCTCAGGTGACAT) and control
202 mismatched oligonucleotides (MM oligos) (CCGCTCATCACTGCTGACAT) were synthesized by
203 Integrated DNA Technologies (IDT). All 20-base oligonucleotides were designed to avoid
204 murine immune-stimulatory motifs, and contained phosphorothioate backbones and 2'-O-
205 methoxyethylribose (MOE)-modification on bases 1–5 and 16–20 as described previously.^{40,41}
206 Oligonucleotides were suspended in sterile saline and administered every 3 days (40 mg/kg,

207 total volume 10 μ L saline/g body weight) by intraperitoneal injection.⁴¹ Male C57BL/6 sham-
208 operated and HF mice (4 w post-MI) with comparable degrees of LV remodeling were
209 randomized to receive either IL-4R α ASOs (Ref 219428745, IDT) or MM oligos (Ref 219428746,
210 IDT) for 4 w.

211 ***In vivo* phagocytosis assay.** To assess cardiac macrophage phagocytosis *in vivo*,
212 pHrodo™ green-E. coli bioparticles (Invitrogen, P35366) were injected intraperitoneally to mice
213 (200 μ g/mouse) 4 h before sacrifice. After sacrifice, heart mononuclear cells were collected and
214 cell surface marker staining performed with anti-mouse CD45, F4/80, MERTK and CD206 as
215 described above. Bioparticle uptake in live macrophages was measured by flow cytometry.

216 **Cardiac mesenchymal stem cell (cMSC) studies *in vitro*.** Sca1⁺CD90⁺CD31⁻DDR2⁻
217 cMSCs were isolated from mouse hearts and maintained in supplemented [DMEM]/Ham's F-12
218 culture medium as previously described,³³ and used within 3-5 cell passages for all experiments.
219 For isolated cell stimulation studies, cMSCs were treated at the indicated times with serum-free
220 conditioned RPMI 1640 medium from M0, M[IL-4], or M[IL-10] macrophages described above
221 (or control media alone), with some experiments performed in the presence of either 1.5 μ g/mL
222 Fizz1 neutralization antibody or IgG isotype control (antibodies-online.com, ABIN636644 and
223 ABIN1881001, respectively). In separate studies, cMSCs were treated with recombinant mouse
224 Fizz1 (Leinco Technologies, R1140) at the indicated concentrations and times in serum-free
225 RPMI 1640 medium.

226 **Collagen gel-contraction assays.** These were performed as previously described.³³
227 Briefly, cMSCs in ice-cold 10% FBS DMEM medium mixed with 1 mg/mL rat tail collagen I were
228 plated in 48-well tissue culture plates at a density of 3×10^5 cells/well. The cell suspension was
229 incubated at 37°C for 30 minutes until gelation. After gel formation, an additional 0.5 mL of 10%
230 FBS DMEM medium was added to each well and incubated overnight at 37°C in a 5% CO₂
231 incubator. The supernatant was then removed and the gels treated with 0.5 mL conditioned

232 RPMI 1640 medium from M0, M[IL-4], or M[IL-10] macrophages with 10% FBS (or media alone
233 control), with or without anti-Fizz1 or IgG isotype control (1.5 μ g/mL), as described above. Some
234 experiments were performed upon incubation with IL-4 or IL-10 alone (40 ng/mL) in 10% FBS
235 RPMI 1640 medium. The cells were cultured and treated for 5 d with medium change every 2 d.
236 On day 5, the gels were detached from the wells using a pipette tip and incubated overnight. On
237 day 6, the gels were imaged with a digital camera and gel area was measured using Image J
238 software (1.51j8, NIH).

239 **siRNA transfection of cMSCs.** cMSCs were transfected with siRNA using INTERFERin
240 Reagent (Polyplus, 101000028) according to the manufacturer's protocol. Control siRNA
241 (4390843) and siRNA targeting Notch1 (4390771) were purchased from Invitrogen.

242 **Cardiac fibroblast studies *in vitro*.** Mouse cardiac fibroblasts were purchased from
243 iXCells biotechnologies (10MU-015) and grown in fibroblast growth medium (MD-0011) at 37°C
244 in a humidified 5% CO₂ atmosphere. Cells were used within 1-3 passages and treated with M0,
245 M[IL-4], or M[IL-10] conditioned medium for 24 h.

246 **Human studies.** Following patient consent, failing heart tissue was procured from
247 patients with advanced (NYHA IV) HF with reduced EF undergoing LV assist device (LVAD)
248 placement at the University of Alabama at Birmingham (UAB) under the auspices of Institutional
249 Review Board (IRB) approved protocol #X090810003. Non-failing control heart tissues were
250 obtained from donor hearts technically unsuitable for heart transplantation from the Alabama
251 Organ Center. All protocols using human heart samples were approved by the UAB IRB. Failing
252 and control human heart tissues were used for cardiac immune cell isolation and subsequent
253 flow cytometry, as well for histological analysis. Clinical characteristics of human HF subjects
254 and donor controls are shown in [Supplemental Table 3](#).

255 **Statistical Analysis.** All group data are mean \pm SD. All statistical analyses were
256 performed with GraphPad Prism 9 (GraphPad Software). Normality was assessed using the
257 Shapiro-Wilk test, whereas group variances were compared using the Brown-Forsythe test. For

258 normally distributed data, a two-tailed unpaired Student's *t* test with equal or unequal variance
259 was used for two-group analyses, and 1- or 2-way ANOVA with Tukey's post-test was used for
260 multi-group analyses. Additionally, 2-way repeated-measures ANOVA with Dunnett's multiple
261 comparison test was used to analyze time series pre-post data. For non-normal distributions,
262 the Mann-Whitney U test was used for 2-group analyses. Pearson R correlation test was used
263 for linear dependence analyses. Specific approaches are in the figure legends. A *p* value
264 of <0.05 was considered statistically significant.

265 RESULTS

266 **Cardiac CD206⁺ macrophages progressively expand during the development of**
267 **chronic HF post-MI.** Cardiac macrophage subsets were profiled using flow cytometry at
268 various timepoints following non-reperfused large MI during the development of ischemic
269 HF,^{4,26,29,36} and in sham-operated controls (*Figure 1A*). As shown in *Figures 1B-C and S1A*,
270 following MI there was significant cardiac accumulation of both overall CD45⁺ leukocytes and
271 total F4/80⁺MERTK⁺ macrophages in a biphasic manner, with high levels at 48 h after injury,
272 subsequent decline by 2 w, followed by a second phase of re-expansion up to 8 w post-MI
273 during chronic LV remodeling and failure. In the failing heart 8 w post-MI, macrophages
274 comprised nearly two-thirds (~63%, or ~140,000 cells per heart) of all cardiac leukocytes and
275 were increased by ~9-fold over macrophage levels in sham-operated hearts. Similar dynamics
276 were observed for the blood levels of pro-inflammatory Ly6C^{high} monocytes, an important source
277 of infiltrating macrophages,^{3,5,10,32,42} during the progression of ischemic HF. No significant
278 differences were observed in the levels of patrolling Ly6C^{low} monocytes between sham-operated
279 and HF mice at any time point evaluated (*Figures S2A-C*).

280 We next further evaluated macrophage subsets in the mouse heart. Naïve murine hearts
281 harbored low numbers of macrophages (~20,000/heart), of which ~90% expressed the resident
282 macrophage marker CD206 (*Figure 1C*). However, acutely (48 h) after MI, CD206⁺
283 macrophages comprised only ~20% of overall macrophages in the heart, in the setting of a

284 marked expansion of CD206⁻ macrophages early after MI. Thereafter, both the frequency and
285 absolute number of CD206⁺ macrophages steadily increased in post-MI hearts during the
286 progression of LV remodeling, such that at 8 w post-MI ~85% of cardiac macrophages
287 expressed CD206. In contrast, CD206⁻ macrophage levels decreased markedly by 2 w post-MI,
288 and then exhibited smaller sustained increases in chronically failing hearts thereafter. Both
289 populations were significantly increased as compared to sham-operated hearts at all timepoints
290 post-MI. Hence, macrophages expand significantly in the chronically remodeled and failing heart
291 post-MI, and most of these macrophages express CD206.

292 **Cardiac CD206⁺ macrophages robustly express IL-4R α in chronic HF.** Two key
293 activators of CD206⁺ macrophages are IL-4/13, acting via Type I or II IL-4 receptors (IL-4R)
294 containing the common subunit IL4R α ,⁴³⁻⁴⁵ and IL-10, signaling through the IL-10 receptor (IL-
295 10R) complex upon binding to the high affinity IL-10R α (IL-R1) subunit.^{46,47} As illustrated in
296 Figure 1D, both CD206⁺IL4R α ⁺ and CD206⁺IL-10R α ⁺ macrophage subpopulations were
297 significantly increased in comparison to sham-operated hearts at all time points after MI.
298 However, there was substantial expansion of the CD206⁺IL4R α ⁺ population over time, such that
299 at 8 w post-MI, levels of CD206⁺IL-4R α ⁺ cells (~45,000 per heart) were ~8-fold higher than
300 CD206⁺IL-10R α ⁺ cells and comprised ~42% of all CD206⁺ macrophages in the chronically failing
301 heart. In contrast, at 1 w post-MI, during the healing phase, CD206⁺IL-10R α ⁺ macrophages
302 were more abundant than CD206⁺IL-4R α ⁺ cells, comprising ~40% of all CD206⁺ macrophages
303 in the heart. Notably, neither IL-4R α nor IL-10R α were abundantly expressed by cardiac
304 CD206⁻ macrophages (<3% of cells) at any timepoint post-MI, and CD206⁻ macrophages
305 expressing either IL-4R α or IL-10R α numbered fewer than 500 cells/heart in the chronic stages
306 of LV remodeling (Figure S1B). In addition, IL-4R α and IL-10R α expression was also very low in
307 blood neutrophils (<1.5%), Ly6C^{low} monocytes (<2%) and Ly6C^{high} monocytes (<5%) in both
308 sham and HF mice (Figure S2).

309 Regarding Th2 cytokines, serum levels of IL4 and IL-10 were significantly higher in MI
310 mice as compared with sham mice during both the healing phase (1 w) and chronic remodeling
311 phase (8 w) post-MI, whereas levels of IL-13 and TGF- β 1 were comparable in sham and MI
312 mice at all timepoints (*Figure S3A*). In contrast, serum levels of the pro-inflammatory cytokines
313 TNF- α , IFN- γ , IL-1 β , MCP-1 and MIP-2 α in HF mice were increased over sham controls during
314 both the early and late phases of remodeling after MI (*Figure S3B*), consistent with ongoing
315 systemic inflammation in HF mice. Hence, CD206⁺ macrophages in the failing heart primarily
316 express IL-4R α (versus IL-10R α); this is accompanied by increased circulating levels of both IL-
317 4 and IL-10.

318 **CD206⁺ macrophages in the failing heart proliferate, are primarily CCR2⁻, MHCII^{hi},**
319 **and LYVE1⁺ and correlate with LV dysfunction and fibrosis.** At 8 w post-MI, HF mice
320 exhibited significant LV systolic dysfunction and fibrosis (*Figure 2A and S4A*). Cardiac CD206⁺
321 macrophage abundance inversely correlated with LVEF ($r = 0.695$), and directly correlated with
322 border and remote zone fibrosis ($r = 0.755$ and 0.644 , respectively). Tissue co-staining with anti-
323 CD206 and fluorescein-conjugated collagen hybridizing peptide (CHP) that recognizes
324 denatured collagen⁴⁸ revealed that CD206⁺ macrophages were primarily found in areas of
325 collagen turnover in the failing heart, with >98% of macrophages associated with CHP-positive
326 regions in the infarct and border zones, and >80% CHP-associated cells in the remote
327 myocardium (*Figure 2B*). To infer the source of CD206⁺ macrophage expansion in the failing
328 heart, we measured the expression of markers CCR2, MHCII, and LYVE1 by flow cytometry
329 (*Figure 2C*). In sham hearts, >90% CD206⁺ macrophages were CCR2⁻, and of these, ~95%
330 were LYVE-1⁺, indicating a primarily resident macrophage population. In failing hearts, the
331 proportion of CD206⁺CCR2⁻LYVE1⁺ macrophages decreased significantly but remained high at
332 ~80% of total CD206⁺ cells, suggesting resident cell predominance but with an increased

333 contribution from monocyte-derived macrophages. Moreover, in both sham and failing hearts,
334 the majority (~70%) of CD206⁺ macrophages were MHCII^{hi}.

335 Resident macrophage expansion requires local cell proliferation. As shown in Figure 2D
336 and S4B, immunostaining for CD206 and the cell proliferation marker Ki67 revealed that both
337 total CD206⁺ and Ki67⁺CD206⁺ macrophages were robustly expanded in the failing heart (8 w
338 post-MI) as compared to sham. Cell density was greatest in the infarct zone (855 cells/mm²; 9%
339 Ki67⁺), followed by the border zone (584 cells/mm²; ~8% Ki67⁺) and then the remote zone (290
340 cells/mm², Ki67 positivity ~3% similar to sham hearts). Complementary assessment using flow
341 cytometry demonstrated that in both sham and failing hearts only CD206⁺ macrophages
342 exhibited Ki67 positivity (Figure 2E). Moreover, as compared to sham, failing hearts evidenced
343 ~3-fold higher levels of CD206⁺Ki67⁺ macrophages (~10% total), confirming augmented local
344 proliferation of CD206⁺ macrophages. In parallel, myocardial gene expression of Th2 cytokines
345 IL-4 and IL-10 (but not IL-13) and classical alternatively-activated macrophage markers *Mrc1*
346 (*CD206*), *Arg1*, *Ym1* and *Fizz1* was significantly increased in failing versus sham hearts (Figure
347 S4C). Concomitantly, the expression of fibrotic genes (*Col1α1*, *Col1α2*, and *Col3α1*) was
348 markedly increased in failing hearts. Collectively, these data support expansion of a Th2/M2-like
349 immuno-fibrotic response in the chronically failing heart post-MI.

350 **IL-4 polarization *in vitro* induces a profibrotic phenotype in CD206⁺ macrophages.**

351 Bone marrow-derived macrophages (BMDMs) were polarized with either IL-4 or IL-10
352 (40ng/mL), or medium alone (M0 control), for 24 h (Figure 3A). Flow cytometry indicated that
353 while BMDMs were primarily CD206⁺ under resting (M0) conditions, both IL-4 and IL-10
354 exposure augmented BMDM CD206 expression to ~98-99% of total cells. As shown in Figure
355 3B, the expression of signature M2 genes^{15,18,20,49,50} *Mrc1*, *Arg1*, and *Ym1* significantly increased
356 in both M[IL-4] and M[IL-10] macrophages (with much more *Arg1* and *Ym1* expression in M[IL-4]
357 cells) as compared to non-polarized M0 macrophages. In contrast, expression of *Fizz1* (found in
358 inflammatory zone 1), a protein secreted during Th2 responses^{51,52} and implicated in

359 myofibroblast differentiation and lung fibrosis,^{53,54} only increased in M[IL-4] macrophages, and to
360 extraordinary levels (>7,500-fold). Conversely, *B7-H4* was exclusively, albeit modestly,
361 upregulated in M[IL-10] macrophages. Changes in macrophage gene expression were noted
362 after 4 h of polarization (Figure S5A) and were maintained or augmented after 48 h (Figure
363 S5B). A range of responses was observed for inflammatory and repair-associated genes in
364 BMDMs after 24 h of polarization *in vitro* (Figure S6A). Surprisingly, there was no upregulation
365 of profibrotic genes TGF- β 1 and platelet-derived growth factor (PDGF)-BB in M[IL-4] and M[IL10]
366 macrophages as compared to M0 cells, although there was augmented expression of tissue
367 inhibitor of matrix metalloproteinase (TIMP)-1 and TIMP-3 in both M[IL-4] and M[IL-10]
368 macrophages.

369 In parallel experiments, conditioned medium was collected from M0, M[IL-4] and M[IL-10]
370 macrophages and applied to Sca1⁺CD90⁺CD31⁻DDR2⁻ cardiac MSCs³³ (Figure 3A). cMSC
371 gene expression was then evaluated after 6 and 16 h of exposure. Short-term (6 h) exposure to
372 M[IL-4] medium induced significant upregulation of the proliferation genes *PCNA*, *Mki67*,
373 *CyclinB1* and *CyclinD1* as compared to M0-medium, and to a greater extent than upon
374 exposure to M[IL-10] medium. Longer-term (16 h) exposure induced similar expression
375 responses for cMSC pro-fibrotic genes, including α -smooth muscle actin (*α -SMA*), *Col1 α 1*,
376 *Col1 α 2*, and *Col3 α 1* (Figure 3C). The functional impact of macrophage polarization on cMSCs
377 was assessed using collagen gel contraction assays³³ after 5 d of exposure to M0, M[IL-4],
378 M[IL-10] medium, or medium alone control. As illustrated in Figure 3D, M[IL-4] medium
379 exposure induced robust gel contraction, significantly greater than with exposure to either M0 or
380 M[IL-10] medium (or control), consistent with vigorous cMSC myofibroblast differentiation.
381 Importantly, exposure to complete medium containing IL-4 or IL-10 alone (40 ng/mL) did not
382 induce cMSC gel contraction (Figure S6B), indicating an indispensable role for CD206⁺
383 macrophages in IL-4-induced cMSC myofibroblast differentiation. Similarly, 24 h treatment with

384 M[IL-4] medium robustly increased α -SMA protein expression in mouse cardiac fibroblasts as
385 compared with similar treatment with M0 or M[IL-10] medium (*Figure S6C*). Collectively, these
386 data suggest that IL-4-mediated macrophage polarization supports pro-fibrotic responses in
387 concert with striking upregulation of *Fizz1*.

388 **Adoptive transfer of M[IL-4] macrophages to naïve hearts induces cardiac**
389 **dysfunction and fibrosis.** To evaluate the in vivo cardiac effects of M[IL-4] and M[IL-10]
390 macrophages, we adoptively transferred 1×10^6 M0, M[IL-4], or M[IL-10] bone marrow-derived
391 macrophages from CD45.2 male mice to naïve WT CD45.1 male mice (PBS control) via
392 intramyocardial injection, with subsequent follow-up over 4 w (*Figure 4A*). Immunostaining of
393 injection sites of recipient hearts 30 minutes post-injection confirmed successful transfer of M0,
394 M[IL-4], and M[IL-10] donor macrophages (*Figure S7A*). Serial echocardiography of recipient
395 mice revealed progressive and significant LV chamber dilatation, with increased EDV and ESV,
396 and systolic dysfunction, with reduced LVEF, along with LV hypertrophy, evidenced by
397 increased LV mass, IVSWTd, and PWTd by echocardiography and increased normalized heart
398 weight, in M[IL-4] macrophage recipients, but not in PBS, or M0 or M[IL-10] macrophage
399 recipients (*Figures 4B and S7B and D*). Stroke volume was comparable over time in all four
400 groups (*Figure S7C*). Histological analysis showed significantly increased patchy interstitial
401 fibrosis in M[IL-4]-recipient hearts as compared with PBS, M0, and M[IL-10] recipient hearts
402 (*Figure 4C*), along with augmented cardiomyocyte cross-sectional area and apoptosis (*Figures*
403 *4D and S7E*). Importantly, CD45.2 and CD206 co-staining of recipient hearts demonstrated
404 donor macrophage persistence in adoptive transfer recipients, but to a significantly greater level
405 in M[IL-4] recipient mice. M[IL-4] (but not M0 or M[IL-10]) macrophage transfer also induced
406 expansion of native resident CD206⁺ macrophages. Both CD45.2⁺ donor and CD45.2⁻ recipient
407 CD206⁺ macrophages expansion occurred primarily at sites of collagen turnover and fibrosis in
408 recipient hearts, with stronger such association for donor macrophages (*Figures 4E and S7F*),

409 There was no evidence of pro-inflammatory Ly6C^{hi} monocytosis in any recipient mouse group
410 (*Figure S7G*), suggesting the absence of systemic inflammation after transfer. Collectively,
411 these data establish that M[IL-4] polarized macrophages are sufficient to induce chronic cardiac
412 remodeling, hypertrophy, and fibrosis, and a microenvironment supporting CD206⁺ macrophage
413 expansion.

414 **Myeloid-specific IL-4R α deletion in HF suppresses cardiac CD206⁺ macrophage**

415 **expansion and improves LV remodeling.** Among myeloid cells, IL-4R α expressions occurred
416 primarily in macrophages, with low levels in monocytes and neutrophils (*Figure S2*), and among
417 macrophages, primarily in CD206⁺ macrophages (*Figures 1D and S1B*). Hence, to establish the
418 role of CD206⁺IL4R α ⁺ macrophages in HF, we used IL-4R α ^{ff}LysM-Cre^{ERT2} mice. Given the
419 importance of the IL-4 axis in wound healing after acute MI^{15,24} and our observations that
420 cardiac CD206⁺IL-4R α ⁺ macrophage expansion in ischemic HF occurs most prominently ≥ 4 w
421 post-MI, we induced myeloid IL-4R α deletion during late remodeling. Male and female IL-4R α ^{ff}
422 and IL-4R α ^{ff}LysM-Cre^{ERT2} HF mice with comparable LV remodeling at 4 w post-MI (or sham-
423 operated controls) were randomized to receive tamoxifen diet for 6 weeks (*Figure 5A*). In male
424 mice, echocardiography revealed significant LV dilation and systolic dysfunction in both HF
425 groups 4 w post-MI as compared to sham (*Figure 5B*). In contrast, as compared with tamoxifen-
426 fed IL-4R α ^{ff} HF mice, tamoxifen treatment for 6 w in IL-4R α ^{ff}LysM-Cre^{ERT2} HF mice resulted in
427 lower LVEDV and ESV, better LVEF and stroke volume (SV), and smaller heart size and
428 normalized heart and lung weight (*Figures 5B, S8A-B*). Moreover, histological analysis revealed
429 less border and remote zone fibrosis, smaller cardiomyocyte area, and improved capillary
430 density in male IL-4R α ^{ff}LysM-Cre^{ERT2} HF mice versus IL-4R α ^{ff} HF mice (*Figures 5C, S8C*).
431 Myeloid IL-4R α deletion in HF in male mice also decreased levels of total leukocytes, CD206⁺
432 and CD206⁻ (and CD206⁻IL4R α ⁺) macrophages, CD206⁺IL4R α ⁺ and CD206⁺IL10R α ⁺
433 macrophages, and proliferating Ki67⁺CD206⁺ macrophages in the heart, as well as Ly6C^{hi} and

434 Ly6C^{hi}IL-4R α ⁺ monocytes (but not Ly6C^{low} monocytes) in the blood, as compared to HF mice
435 without myeloid IL-4R α deletion (*Figures 5D-F, S8D-F*). There were no effects of myeloid IL-
436 4R α deletion on any parameter in sham male mice.

437 Comparable tamoxifen-induced effects were observed in female IL-4R α ^{f/f}LysM-Cre^{ERT2}
438 versus IL-4R α ^{f/f} HF mice with regard to improvements in LV remodeling and systolic function
439 (albeit with less pronounced differences in LVEDV) (*Figure S9A-B*), heart and lung gravimetry
440 and weight (*Figure S9C-D*), and reductions in cardiac leukocytes and total macrophages (Figure
441 S10A), CD206⁺ and CD206⁻ macrophages, CD206⁺IL4R α ⁺ and CD206⁺IL10R α ⁺ macrophages,
442 and CD206⁻IL4R α ⁺ macrophages (*Figures S10B-C*). As in males no effects of myeloid IL-4R α
443 deletion on any of these parameters were observed in sham-operated female mice. Collectively,
444 these results indicate that CD206⁺IL4R α ⁺ macrophages are a key expanded myeloid cell
445 population in the failing heart that is necessary for driving progressive inflammation and
446 pathological cardiac remodeling, fibrosis, and dysfunction. Moreover, IL-4R α expression marks
447 a macrophage subpopulation with high proliferative capacity in the failing heart.

448 **IL-4R α silencing *in vivo* reverses LV remodeling, reduces cardiac fibrosis, and**
449 **improves neovascularization in HF.** To explore whether the macrophage IL-4R α axis could
450 be exploited for therapeutic benefit in HF, we selectively silenced IL-4R α expression *in vivo*
451 using optimized antisense oligonucleotides (ASOs) targeting IL-4R α mRNA.^{40,41} IL-4R α
452 signaling mainly occurs in hematopoietic and lymphoid cells.⁴⁵ In humans, there is very low IL-
453 4R RNA expression in heart cardiomyocytes and fibroblasts, with much more pronounced
454 expression in immune cells, and in endothelial and smooth muscle cells
455 (<https://www.proteinatlas.org/ENSG00000077238-IL4R/single+cell+type/heart+muscle>). To
456 assure targeting of cardiac macrophages with this systemic approach, we performed flow
457 cytometry to evaluate IL-4R α expression in cardiac leukocytes. As shown in *Figure S11*, in both
458 sham and failing hearts, ~92% of all IL-4R α ⁺ CD45⁺ leukocytes were macrophages

459 (F4/80⁺MERTK⁺), while ~98% of IL-4R α ⁺ macrophages in failing hearts were CD206⁺. Moreover,
460 circulating monocytes and neutrophils exhibited low levels of IL-4R α expression (*Figure S2*).
461 Hence, IL-4R α ASOs represent a feasible and directed approach for dual inhibition of IL-4 and
462 IL-13 signaling⁴⁵ in cardiac CD206⁺IL-4R α ⁺ macrophages.

463 Male sham-operated and HF mice with comparable degrees of LV remodeling at 4 w post-
464 MI were randomized to receive either IL-4R α ASOs or MM oligos (40 mg/kg every 3 days) for 4
465 weeks (*Figure 6A*). Body weight was comparable between the two sham groups and two HF
466 groups over the 4 w treatment period (*Figure S12A*). Serial echocardiography revealed
467 significant and expected LV dilation and systolic dysfunction in both HF groups as compared to
468 sham groups (*Figures 6B and S12B*). Sham-operated mice exhibited no changes in LVEDV,
469 LVESV, stroke volume (SV), and LVEF during treatment with either IL-4R α ASOs or MM oligos.
470 HF mice treated with MM oligos evidence progressive increases in LV chamber size, and
471 reductions in LVEF and SV, over 4 w. In contrast, HF-IL-4R α ASO mice, which exhibited LV
472 remodeling similar to HF-MM oligo mice at 4 w post-MI, exhibited significant reductions in EDV
473 and ESV, and improvements in SV and EF, indicative of reverse remodeling. Lung and heart
474 gravimetric analysis at 8 w post MI revealed substantially attenuated pulmonary edema and
475 cardiac hypertrophy in HF-IL-4R α ASO HF mice versus HF-MM oligo mice, without impact on
476 spleen weight (*Figures 6C and S12C*).

477 Histological evaluation with trichrome staining indicated significantly increased border and
478 remote zone interstitial fibrosis in MM oligo-treated failing hearts as compared to MM oligo-
479 treated sham hearts (*Figure 6D*). Impressively, IL-4R α ASO treatment profoundly decreased
480 both border and remote zone fibrosis in failing hearts. Fibrotic area in IL-4R α ASO-treated sham
481 hearts was comparable to that of MM oligo-treated sham hearts. Isolectin B4 and wheat-germ
482 agglutinin staining (*Figure 6E*) indicated that both HF-MM oligo mice and HF-IL-4R α ASO mice
483 exhibited significantly increased myocyte cross-sectional area and lower myocardial

484 capillary:myocyte ratio versus their respective sham groups. Importantly, however, myocyte
485 area was lower and capillary:myocyte ratio was higher in HF-IL-4R α ASO mice versus HF-MM
486 oligo mice, indicating alleviation of pathological hypertrophy and capillary rarefaction.

487 **IL-4R α silencing in HF depletes cardiac CD206⁺IL-4R α ⁺ macrophages and**
488 **suppresses their proliferative and phagocytic capacity.** As shown in *Figures S13A and 6F*,
489 4 w of IL-4R α ASO treatment significantly reduced the number of total CD45⁺ leukocytes (by
490 ~45%), total F4/80⁺MERTK⁺ macrophages (by~53%), and both CD206⁺ and CD206⁻
491 macrophages (by ~50%) in the failing heart. Moreover, IL-4R α ASO treatment specifically and
492 profoundly depleted CD206⁺IL-4R α ⁺ cardiac macrophages, while mildly augmenting CD206⁺IL-
493 10R α ⁺ macrophages in the failing heart (*Figure 6F*). IL-4R α ASO administration did not impact
494 leukocyte and total macrophage abundance in sham hearts. Notably, IL-4R α ASO therapy did
495 not impact in circulating IL-4 levels (nor IL-13 and TGF- β 1 levels) in HF mice, whereas serum
496 IL-10 was significantly decreased (*Figures 6G and S13B*). Remarkably, total CD206⁻
497 macrophages, including CD206⁻IL-4R α ⁺ and CD206⁻IL-10R α ⁺ macrophages, in failing hearts
498 were also diminished by IL-4R α ASO treatment (*Figure S13A*). Additionally, IL-4R α ASO
499 treatment impacted CD206⁺ macrophage function in failing hearts, significantly reducing (by
500 ~50%) both CD206⁺ macrophage cell proliferation (Ki67 staining) and phagocytic capacity
501 (assessed in vivo using fluorescent bioparticles) in HF-IL-4R α ASO mice as compared with HF-
502 MM oligo mice (*Figures 6H-I*). The latter data are consistent with IL-4 serving as a potent
503 stimulator of macrophage proliferation.^{15,55}

504 IL-4R α ASO treatment in HF mice also abrogated systemic inflammation as evidenced
505 by normalization of circulating Ly6C^{hi} monocytes (and levels of Ly6C^{hi}IL-4R α ⁺ monocytes) and
506 serum levels of pro-inflammatory protein mediators TNF- α , MCP-1, MIP-2 α and IL-1 β toward
507 those observed in sham mice (*Figure S13C-D*). Serum IFN- γ levels, however, were not
508 impacted by IL-4R α ASO treatment and remained high in HF-IL-4R α ASO mice as compared to

509 sham. Importantly, IL-4R α ASO treatment in HF mice also alleviated T-cell expansion in both
510 the circulation and failing heart, with significant reductions in peripheral blood and cardiac CD4⁺
511 and CD8⁺ T cells in HF-IL-4R α ASO mice as compared with HF-MM oligo mice (Figure S14).
512 Additionally, IL-4R α expression was very low (~1-2%) in blood and heart CD4⁺ and CD8⁺ T cells
513 in both sham and HF mice treated with MM oligo or IL-4R α ASOs. Taken together, these data
514 indicate that in vivo IL-4R α mRNA silencing was highly effective in improving pathological
515 cardiac remodeling, hypertrophy, fibrosis, and dysfunction, and in suppressing local and
516 systemic inflammation in chronic ischemic HF.

517 **Fizz1 is essential for CD206⁺ macrophage-induced myofibroblast activation.** FIZZ1,
518 also known as resistin-like molecule α (*Retnla*), is a 9.4 kDa cysteine-rich secreted protein
519 produced mostly by macrophages during Th2 responses.⁵⁰⁻⁵² As described above, macrophage
520 Fizz1 expression exponentially increased exclusively after M[IL-4] polarization (>7,500-fold after
521 24 h and >100,000-fold after 48 h) polarization and not with M[IL-10] polarization (Figures 3B
522 and S5B), and coincided with M[IL-4] macrophage-induced myofibroblast differentiation of
523 cMSCs (Figure 3C). Accordingly, we further evaluated the role of Fizz1 in pro-fibrotic cellular
524 responses. Exposure of cultured cMSCs to recombinant mouse (rm) Fizz1 induced, in a dose-
525 dependent manner, the expression of proliferative genes *PCNA*, *Mki67*, *CyclinB1* and *CyclinD1*
526 early (2 h), and profibrotic genes *α -SMA*, *Col1 α 1*, *Col1 α 2*, and *Col3 α 1* late (16 h), after
527 treatment (Figure S15), analogous to changes observed with M[IL-4] medium treatment (Figure
528 3C). To determine the need for FIZZ1 in M[IL-4]-induced cMSC responses, we used anti-Fizz1
529 antibody to neutralize endogenous Fizz1 in M[IL-4] conditioned medium. As shown in Figure
530 S16, compared to IgG control, anti-Fizz1 significantly reduced the expression of mitotic genes,
531 *α -SMA* (by 40%) and *Col3 α 1* in M[IL-4] conditioned media-treated cMSCs. Furthermore, anti-
532 Fizz1 abrogated collagen gel contraction induced by M[IL-4] conditioned media (Figure 7A), a

533 phenomenon recapitulated by the use of Fizz1^{-/-} BMDMs (Figure 7B), indicating that secreted
534 Fizz1 is essential for M[IL-4]-induced cMSC myofibroblast differentiation and activation.

535 Notch signaling is critical for cell proliferation, differentiation, and development, and
536 homeostasis;⁵⁶ Notch ligand binding to Notch receptors leads to release of Notch intracellular
537 domain (NICD) and subsequent transcription of target genes, including α -SMA, *Cyclin D1*,
538 *Cyclin A* and NF- κ B.⁵⁶ As α -SMA expression is critical for myofibroblast fate of mesenchymal
539 stromal cells,^{33,57} we assessed the importance of Notch signaling in Fizz1-mediated α -SMA
540 expression in cMSCs. Fizz1 exposure significantly upregulated cMSC gene expression of the
541 Notch1 ligands DLL-4 and Jagged1 within 30 minutes (Figure 7C), followed by increased protein
542 expression of Notch1, NICD and α -SMA within 24 h (Figure 7D). Importantly, Notch1 siRNA
543 knockdown prevented α -SMA (and NICD) upregulation in Fizz1-treated cMSCs, suggesting a
544 critical role for DLL-4/Jagged-Notch1 signaling in the pro-fibrotic effects of M[IL-4] macrophage-
545 secreted FIZZ1.

546 In view of the importance of FIZZ1 in M[IL-4]-induced myofibroblast differentiation, we
547 next examined Fizz1 expression and spatial distribution using immunostaining in failing hearts
548 from MM oligo- and IL-4R α ASO-treated mice (8 w post-MI). Consistent with flow data, a robust
549 (~11-fold) expansion of CD206⁺ macrophages (both IL-4R α ⁺ and IL-4R α ⁻) was observed in MM
550 oligo-treated failing hearts versus sham hearts, especially in the border zone (Figure 7E). IL-
551 4R α staining was observed near exclusively in CD206⁺ cells (Figure S17), further supporting
552 CD206⁺ macrophage-specificity of IL-4R α silencing, and Fizz1⁺ staining was near exclusively
553 spatially localized to IL-4R α ⁺ cells (~98% Fizz1⁺) in all groups (Figure S17). IL-4R α ⁺ Fizz1⁺ cells
554 comprised ~50% cardiac CD206⁺ macrophages in HF-MM oligo mice (Figure 7E). IL-4R α ASO
555 treatment significantly decreased IL-4R α ⁺Fizz1⁺ (and IL-4R α ⁻Fizz1⁻) CD206⁺ macrophages in
556 failing hearts, and also diminished IL-4R α expression (assessed by fluorescence intensity)
557 (Figure 7E). (Figures 7E and Figure S17). Hence, IL-4R α silencing in HF reduced CD206⁺

558 macrophage FIZZ1 expression in the failing heart concomitantly with improvements in cardiac
559 fibrosis. Taken together with the *in vitro* studies above, our results suggest that *Fizz1* may be a
560 key contributor to the tissue level pro-fibrotic effects of CD206⁺IL-4R α ⁺ macrophages in the
561 failing heart.

562 **IL-4R α ⁺Fizz3⁺ alternatively activated macrophages expand and directly correlate**
563 **with fibrosis in human failing hearts.** To understand translational relevance, we lastly
564 explored whether alternatively activated resident macrophages are expanded in human HF. As
565 mentioned above, resident cardiac macrophages express classical M2-like markers *Mrc1*
566 (*CD206*) and *CD163*.^{2,6,13,14} Cardiac mononuclear cells were isolated from the LV apex procured
567 from advanced HF patients during LVAD implantation, and from control donor hearts unsuitable
568 for transplantation. Analogous to murine HF, flow cytometry indicated significant expansion
569 (~10-fold) of CD206⁺ macrophages (CD45⁺Autofluorescence⁺CD64⁺) in human failing hearts
570 versus control, with ~20% of CD206⁺ macrophages expressing CCR2 (Figure 8A). Human
571 failing hearts also exhibited substantial (>200-fold) interstitial fibrosis versus control hearts, with
572 most (~95%) CD163⁺ macrophages found in association with areas of collagen turnover (Figure
573 8B), analogous to murine failing hearts. *Fizz3* (resistin, *Retn*), the human homolog of murine
574 *Fizz1*, is expressed by M[IL-4/13] human macrophages and resembles mouse FIZZ1 with
575 respect to sequence and function.^{58,59} Accordingly, we performed immunostaining for IL-4R α ,
576 *Fizz3* and *CD163*, a widely used marker for alternatively-activated human macrophages.⁶⁰ As
577 shown in Figure 8C, human failing hearts exhibited significant expansion (~6-fold) of CD163⁺
578 macrophages (both IL-4R α ⁺ and IL-4R α ⁻) as compared to control hearts. *Fizz3*⁺ staining was
579 near exclusively spatially localized to IL-4R α ⁺ cells (~98% *Fizz3*⁺) in both human control and
580 failing hearts, similar to the IL-4R α and *Fizz1* expression pattern observed in mouse hearts
581 (Figure S17). Importantly, IL-4R α ⁺*Fizz3*⁺ cells comprised the predominant CD163⁺ macrophage
582 subset in human failing hearts, with approximately two-thirds of CD163⁺ macrophages

583 expressing IL-4R α and Fizz3⁺ (*Figure 8C*). CD163⁺ macrophage abundance directly correlated
584 with cardiac fibrosis in human HF. Hence, analogous to murine HF, human failing hearts also
585 evidence expansion of alternatively activated macrophages, likely with augmented IL-4 signaling
586 and contributing to pro-fibrotic responses.

587 **DISCUSSION**

588 We describe a novel role for cardiac CD206⁺ macrophages alternatively activated by IL-
589 4 receptor signaling in the progression of LV remodeling in ischemic cardiomyopathy. There are
590 several key findings. First, macrophages expressing CD206 comprised most macrophages in
591 the naïve heart. Following MI, cardiac CD206⁺ macrophages progressively expanded, especially
592 during the later stages of LV remodeling such that they comprised the predominant macrophage
593 population in chronic HF. Second, CD206⁺ macrophages were exclusively proliferative and
594 primarily CCR2⁻, MHCII^{hi}, and LYVE1⁺ suggesting a resident cell population, and correlated with
595 LV dysfunction and fibrosis. Second, a sizable subpopulation of these macrophages in HF
596 expressed IL-4R α ; this occurred with attendant increased systemic levels of IL-4. Third, M[IL-4]
597 (but not M[IL-10]) CD206⁺ BMDMs induced remarkable upregulation of *Fizz1*, and robust cMSC
598 myofibroblast differentiation. M[IL-4] CD206⁺ macrophage-induced myofibroblast differentiation
599 and activation were dependent on FIZZ1 secretion and mediated in part by FIZZ1 induction of
600 DLL-4/Jagged1-Notch1 signaling in cMSCs. Fourth, intramyocardial adoptive transfer of M[IL-4]
601 macrophages was sufficient to induce pathological cardiac remodeling and fibrosis. Fifth,
602 myeloid-specific IL-4R α deletion tempered cardiac CD206⁺ macrophage proliferation and
603 alleviated LV dysfunction, fibrosis, and adverse remodeling. Sixth, IL-4R α silencing *in vivo* was
604 highly effective in depleting CD206⁺IL-4R α ⁺ macrophages, reducing FIZZ1 expression in the
605 failing heart, and reversing LV remodeling in mice with established HF. Lastly, humans exhibit
606 expansion of alternatively activated macrophages in the failing heart marked by CD206 and
607 CD163 expression, with predominance of a subpopulation expressing IL-4R α and Fizz3, the

608 human homolog of *Fizz1*. Collectively, these data establish that an expanded pool of
609 alternatively activated CD206⁺IL-4R α ⁺ cardiac macrophages are key drivers of LV remodeling in
610 HF, inducing a Th2/M2-like immuno-fibrotic response in part dependent on FIZZ1. Targeting IL-
611 4 signaling in CD206⁺ macrophages may represent a fruitful therapeutic approach to limit long-
612 term cardiac remodeling in HF.

613 *Mrc1* (*Cd206*) and *Cd163* are typically expressed by resident cardiac macrophages
614 under steady state conditions.^{2,6,13,14} Moreover, in the naïve heart, CD206⁺ macrophages
615 express high levels of classical M2-like genes such as *Ym1* and *Fizz1* and are primarily CCR2⁻
616 ,¹⁵ suggesting a macrophage subset with minimal monocyte-dependence.⁶ Prior work has
617 shown that CD206⁺ macrophages expand during the first week after acute MI in the infarct and
618 border zone to promote infarct repair and functional restoration.¹⁵⁻¹⁷ Administration of IL-4
619 acutely (but not late) after MI also expands CD206⁺ macrophages in the infarcted heart and
620 recapitulates beneficial effects on post-MI cardiac healing.^{15,24} However, the role of this
621 macrophage population, and the impact of macrophage IL-4 signaling, in chronic LV remodeling
622 and ischemic HF has not been defined. The chronically failing heart is typically marked by
623 excessive tissue fibrosis.⁶¹ Notably, in chronic pulmonary,^{62,63} hepatic,⁴¹ and renal²⁵ disease
624 models marked by excessive fibrosis, alternatively activated (CD206⁺ or CD163⁺) macrophage
625 activation mediated by Th2 cytokines such as IL-4 contribute to disease progression. While we
626 have previously shown that the post-MI failing heart exhibits increased IL-4 expression and a
627 predominant Th2 CD4⁺ T-cell profile,²⁶ whether a similar pathophysiological axis contributes to
628 LV remodeling in ischemic cardiomyopathy is unknown.

629 Our studies show that CD206⁺ macrophages progressively expand after MI, with
630 particularly robust levels during the later stages of LV remodeling. Beyond the initial infiltration
631 of predominantly (>80%) CD206⁻ macrophages into the heart early (48 h) after MI, CD206⁺
632 macrophages were the main subtype in the remodeling heart at 1 w post-MI and beyond,

633 comprising ~85% of all macrophages in HF. Moreover, in the failing heart 8 w post-MI, nearly
634 half of all cardiac CD206⁺ macrophages expressed IL-4R α . Notably, cardiac macrophage
635 proliferation was observed exclusively in CD206⁺ subpopulation in the failing heart. Although
636 spatially expanded throughout the myocardium, CD206⁺ macrophages were most abundant in
637 the infarct scar and border zone, and primarily in regions of collagen turnover and fibrosis.
638 Heightened macrophage proliferation was also mainly seen in the scar and border zones. This
639 suggests that progressive CD206⁺ macrophage expansion in these regions may contribute to
640 extracellular matrix remodeling, infarct expansion and LV chamber dilatation over time. Human
641 HF also evidenced marked expansion of alternatively activated (CD206⁺ or CD163⁺) cardiac
642 macrophages (consistent with a prior study of macrophages isolated from human failing hearts⁶⁴)
643 in association with regions of collagen denaturation and turnover, with a predominance of cells
644 expressing IL-4R α analogous to murine HF. In this regard, IL-4 is a known stimulator of tissue
645 macrophage proliferation and resident macrophage self-renewal^{55,65} that also augments
646 macrophage CD206 expression⁶⁶ and promotes M2-like cardiac macrophage differentiation.¹⁵
647 Consistent with our prior studies,²⁶ IL-4 levels were increased both locally in the heart and
648 systemically, suggesting that heightened IL-4 signaling may contribute importantly to sustaining
649 local inflammation and macrophage expansion in failing myocardium.

650 In both murine and human HF, the expanded cardiac CD206⁺ macrophage population
651 was primarily CCR2⁻ (~80%), MHCII^{hi}, and LYVE1⁺. In naïve¹⁵ and in sham-operated hearts,
652 CD206⁺ macrophages were also primarily CCR2⁻, albeit to much greater degrees (~95%) than
653 in failing hearts. As LYVE1 is considered a marker of resident macrophages,⁶ this suggests a
654 predominantly resident macrophage population that is expanded in failing hearts, but also with a
655 dual (albeit lesser) contribution from CCR2⁺ monocyte-derived cells. Prior work has shown that
656 after MI the absence of CCR2 expression does not exclude a monocyte origin as recruited
657 macrophages over time may exhibit transcriptional identities nearly identical to resident

658 macrophages.⁶ Our study design did not incorporate macrophage lineage tracing to definitively
659 address this question. Nonetheless, our data are consistent with prior work indicating that
660 cardiac macrophages derive from both local macrophage proliferation and recruited monocytes
661 (locally-sourced cells comprising ~75%) in chronic ischemic HF.^{3,5} Given our observations that
662 the proportion of CCR2⁺ cells increased significantly in failing hearts, and that cardiac
663 macrophage abundance in post-MI HF was paralleled by similar dynamic changes in Ly6C^{high}
664 blood monocytes that source infiltrating macrophages,^{3,5,6,10} we propose that the expanded and
665 proliferative cardiac CD206⁺ macrophage population derives from both resident and recruited
666 cells.

667 We evaluated the pathophysiological importance of CD206⁺IL-4R α ⁺ expansion in the
668 failing heart by experimentally manipulating IL-4R α signaling, which occurs largely in immune
669 cells.⁴⁵ While both M[IL-4] and M[IL-10] macrophage polarization induced the upregulation of
670 signature alternative macrophage activation genes, M[IL-4] polarization exclusively resulted in
671 extraordinary upregulation of *Fizz1*, and functional myofibroblast differentiation of cMSCs,
672 together with enhanced cMSC proliferative gene expression. Importantly, intramyocardial
673 adoptive transfer of M[IL-4], but not M[IL-10], macrophages produced significant long-term LV
674 chamber dilatation, dysfunction, and fibrosis in naïve recipients. Hence, IL-4-mediated activation
675 of macrophages was sufficient to recapitulate chronic cardiac remodeling.

676 To establish the necessity of CD206⁺IL-4R α ⁺ macrophages in the pathogenesis of
677 chronic LV remodeling, we evaluated the effects of myeloid IL-4R α deletion during established
678 HF on subsequent LV remodeling. This manipulation primarily impacted macrophages in HF,
679 given the very low levels of IL-4R α in neutrophils and monocytes. Notably, loss of macrophage
680 IL-4 signaling via IL-4R α suppressed CD206⁺ macrophage proliferation, abrogated the
681 progression of LV remodeling, improved LV systolic function and fibrosis, while suppressing
682 both CD206⁺ and CD206⁻ macrophages in the heart as well as systemic Ly6C^{hi} monocytosis in

683 the blood. Beneficial effects of macrophage IL-4R α deletion were observed in both male and
684 female mice. Hence, CD206⁺IL4R α ⁺ macrophages are indispensable for sustaining a chronic
685 para-inflammatory response in failing myocardium that drives progressive cardiac remodeling in
686 HF.

687 To explore a potential therapeutic avenue, we performed *in vivo* gene silencing of IL-
688 4R α using ASOs, an approach that primarily targeted cardiac CD206⁺ macrophages given the
689 aforementioned low distribution of IL-4R α expression observed in other myeloid and lymphoid
690 cell populations in chronic HF. IL-4R α silencing in chronic ischemic HF very effectively depleted
691 cardiac CD206⁺IL-4R α ⁺ macrophages and suppressed their proliferation and phagocytic
692 capacity, while inducing impressive reverse LV remodeling with improvements in cardiac fibrosis,
693 neovascularization, and function, and suppression of both local and systemic inflammation (*e.g.*,
694 blood and cardiac CD4⁺ and CD8⁺ T cell levels). Taken together, our results underscore the
695 pathological effects of chronic macrophage IL-4R α activation in the failing heart and establish
696 CD206⁺IL-4R α ⁺ macrophages as key mediators of pathological remodeling of the failing heart.
697 Our data support biological or pharmacological blockade of the IL-4/IL-4R α pathway as a novel
698 immunomodulatory paradigm in HF. For instance, antagonistic antibodies against IL-4R α are
699 currently being developed for allergic disorders in humans,⁶⁷ and could potentially be
700 repurposed for HF.

701 CD206⁺ macrophage abundance in murine failing hearts (or CD163⁺ macrophage
702 abundance in human HF) correlated with the extent of cardiac fibrosis in chronic HF, and a
703 prominent feature of IL-4-mediated CD206⁺ macrophage activation *in vitro* and *in vivo* was the
704 induction of pro-fibrotic responses. Our data suggest that the protein FIZZ1 secreted by M[IL-4]
705 macrophages may play an important role in this crosstalk, given: 1) *in vitro* studies
706 demonstrating incredibly robust macrophage *Fizz1* upregulation upon IL-4 stimulation, 2) FIZZ1
707 dependence of the induction of cMSC myofibroblast differentiation by M[IL-4] macrophages,

708 potentially via DLL-4/Jagged1-Notch1 signaling, 3) exclusive expression of Fizz1 by cardiac
709 CD206⁺IL-4R α ⁺ macrophages in chronic HF, and 4) exclusive expression of FIZZ3 (resistin),
710 the human homolog of FIZZ1,⁵⁸ by CD163⁺IL-4R α ⁺ macrophages in human failing hearts. FIZZ1
711 is secreted during Th2-type immune responses in mice.^{52,68} and induces myofibroblast
712 differentiation and fibrosis in the lung,^{53,54} whereas FIZZ3 induces LV fibrosis and dysfunction
713 when overexpressed in rat heart⁶⁹ and is a serum risk prediction biomarker in HF patients.⁷⁰ Our
714 data are consistent with a key pro-fibrotic function for FIZZ1 in the failing heart, secreted by
715 alternatively-activated CD206⁺IL-4R α ⁺ macrophages as part of an overall Th2/M2-like
716 inflammatory milieu in the failing heart.²⁶ The elucidation of the precise role of Fizz1/Fizz3, and
717 the potential for therapeutic Fizz1/Fizz3 blockade in HF, will require further study.

718 In summary, we have established a novel immunoinflammatory framework in the failing
719 heart with an expanded pool of alternatively activated CD206⁺IL-4R α ⁺ macrophages as key
720 drivers of LV remodeling. These alternatively-activated macrophages induce a para-
721 inflammatory, immuno-fibrotic response, in part dependent on FIZZ1 expression, that promotes
722 cardiac fibrosis and dysfunction. Our findings identify IL-4 signaling in CD206⁺ macrophages,
723 and potentially FIZZ1/FIZZ3 elaboration, as novel and appealing therapeutic targets for
724 immunomodulation to limit long-term cardiac remodeling in ischemic cardiomyopathy and HF.

725

726 **ACKNOWLEDGEMENTS AND FUNDING**

727 This work was supported by National Institutes of Health R01 HL157999 and HL147549
728 grants to SDP, and R01 HL137046 to TH.

729

730 **COMPETING INTERESTS**

731 There are no relevant author financial interests.

732

733 **FIGURE LEGENDS**

734 **Figure 1. Cardiac CD206⁺ macrophages robustly expand and express IL-4R α in**
735 **heart failure (HF). A**, Protocol for cardiac macrophage profiling by FACS in C57BL/6 mice at
736 the indicated time points after non-reperfused myocardial infarction (MI) or sham operation. **B**
737 and **C**, representative flow cytometry scatter plots (**B**) and group quantitation for cardiac
738 macrophages (F4/80⁺MerTK⁺), and CD206⁺ and CD206⁻ subpopulations (**C**) from sham and MI
739 mice at the indicated times post-operation. Quantitation from naïve mice also shown. **D**,
740 Representative flow plots and group data for IL-4R α and IL-10R α expression in cardiac CD206⁺
741 macrophages from the same mouse groups. Statistics: unpaired Student's t test; ** $p < 0.01$ vs
742 respective sham group in **C-D**; \$\$ $p < 0.01$ vs Sham-CD206⁻ in **C**, \$\$ $p < 0.01$ vs Sham-IL-10R α ⁺ in
743 **D**. N=6-8 per group.

744 **Figure 2. Cardiac CD206⁺ macrophages are proliferative, primarily MHCII^{hi} and**
745 **LYVE1⁺, and correlate with LV dysfunction and fibrosis in heart failure (HF). A**,
746 Representative long-axis 2-dimensional echocardiograms at end-diastole and heart trichrome
747 stains from HF mice 8 w after non-reperfused myocardial infarction (MI) and sham controls,
748 along with correlations between cardiac CD206⁺ macrophage number and LV ejection fraction
749 (LVEF), and border and remote zone (BZ and RZ) fibrosis in failing hearts. **B**, Representative
750 low and high magnification confocal images of failing heart (8 w post-MI) infarct, border, and
751 remote zones (immuno)stained for CD206 (red) and collagen hybridizing peptide (CHP) (green),
752 with quantitation of CHP-associated and -unassociated CD206⁺ macrophages. DAPI (blue) was
753 used to label nuclei. Scale bar 50 μ m. **C**, Flow plots and quantitation of CCR2 and LYVE1
754 expression in CD206⁺ macrophages and LYVE-1 expression in CD206⁺CCR2⁻ macrophages in
755 sham and HF hearts 8 w post-surgery, **D**, Low and high magnification confocal images of
756 CD206 (red) and Ki67 (green) immunostains of sham, and the infarct, border and remote zones
757 of failing hearts 8 w post-surgery, and quantitation of CD206⁺ macrophages and Ki67

758 expression frequency. Nuclei labeled by DAPI (blue); yellow arrows indicate CD206⁺Ki67⁺ cells.
759 Scale bar 50 μ m. **E**, Flow plots and quantitation of Ki67 expression in both CD206⁺ and CD206⁻
760 cardiac macrophages from the same groups. Statistics: Pearson R correlation test in **Aa**;
761 unpaired Student's t test in **C-E**. N=4-13 per group as indicated.

762 **Figure 3. IL-4-polarized bone marrow derived macrophages (BMDMs) induce**
763 **cardiac mesenchymal stem cell (cMSC) myofibroblast differentiation *in vitro*.** **A**, Protocol
764 for BMDM polarization and cMSC treatment with macrophage conditioned medium, and
765 representative flow plots of F4/80 and CD206 expression in polarized BMDMs. **B**, Expression of
766 the indicated genes in M0, M[IL-4], and M[IL-10] macrophages 24 h after polarization. **C**,
767 Expression of the indicated genes in cMSCs treated with M0, M[IL-4], and M[IL-10] conditioned
768 media for the indicated times, and representative cMSC-imbued collagen gel contraction assays
769 upon exposure to M0, M[IL-4], and M[IL-10] conditioned media, or media alone (Ctrl), and
770 quantitation of gel areas. Statistics: 1-way ANOVA with post-hoc Tukey's multiple comparison
771 test; * $p < 0.05$, ** $p < 0.01$ vs. M0. N=5-6/group.

772 **Figure 4. Adoptive transfer of M[IL-4] macrophages to naïve hearts induces**
773 **cardiac dysfunction and fibrosis.** **A**, Protocol for intramyocardial adoptive transfer of M0,
774 M[IL-4], and M[IL-10] bone marrow derived macrophages (BMDMs) or PBS vehicle to naïve
775 mice. **B**, M-mode echocardiograms of M0, M[IL-4], and M[IL-10] BMDM recipient mice 4 w post-
776 transfer (PBS control), along with group data for LV end-systolic and end-diastolic volume (ESV
777 and EDV), ejection fraction (EF) at indicated times post-transfer, and for echocardiographic LV
778 mass normalized to tibia length (TL), and end-diastolic interventricular septal and posterior wall
779 thickness (IVSWT and PWT) at 4 w post-transfer. **C**, Representative trichrome stains of
780 recipient hearts at 4 w post-transfer and corresponding quantitation of cardiac fibrosis. **D**, *Top*,
781 cardiac wheat-germ agglutinin (WGA, red) staining and quantitation of myocyte cross-sectional
782 area; *Middle*, low and high magnification images of TUNEL (green) stained nuclei in
783 cardiomyocytes (α -Actinin, Red) and quantitation of apoptotic myocyte nuclei; and *Bottom*, Low

784 and high magnification confocal images of CD206 (red) and CD45.2 (gray) immunostains and
785 quantitation of CD206⁺CD45.2⁺ and CD206⁺CD45.2⁻ macrophages in recipient hearts, all at 4 w
786 post-transfer. Green arrows indicate apoptotic myocyte nuclei, red arrows indicate
787 CD206⁺CD45.2⁻ cells, and white arrows indicate CD206⁺CD45.2⁺ cells. DAPI (blue) was used to
788 label nuclei. **E**, Low and high magnification confocal images of CD206 (red) and CD45.2 (gray)
789 immunostaining and CHP staining (green), and quantitation of CHP-associated and -
790 unassociated, CD45.2⁺ and CD45.2⁻ CD206⁺ macrophage ratios in M[IL-4] recipient hearts 4 w
791 post-transfer. Nuclei were labeled by DAPI (blue). Red arrows indicate CHP-unassociated
792 CD206⁺CD45.2⁻ cells and white arrows indicate CHP-unassociated CD206⁺CD45.2⁺ cells.
793 Statistics: repeated-measures 1-way ANOVA with post-hoc Dunnett's multiple comparison test
794 for time series within groups in **B**, 1-way ANOVA with post-hoc Tukey's multiple comparison test
795 between groups in **B-D**, and unpaired Student's t test in **E**; * $p < 0.05$, ** $p < 0.01$ M[IL-4] vs. PBS;
796 # $p < 0.05$, ## $p < 0.01$ M[IL-4] vs. M0; \$ $p < 0.05$, \$\$ $p < 0.01$ M[IL-4] vs. M[IL-10]; $\Delta p < 0.05$, $\Delta\Delta p < 0.01$ vs.
797 Bsln. N=6-8 per group as indicated.

798 **Figure 5. Myeloid-specific IL-4R α deletion suppresses cardiac CD206⁺**
799 **macrophages and alleviates LV remodeling in heart failure (HF). A**, Protocol for myeloid-
800 specific IL-4R α ablation in IL-4R α ^{ff}LysM-Cre^{ERT2} sham and HF mice (IL-4R α ^{ff} mouse control)
801 with tamoxifen administration in diet from 4 to 10 w post-MI or sham surgery. **B**, Representative
802 long-axis 2D echocardiograms at end-diastole from male sham and HF mice after 6 w of
803 tamoxifen (10 w post-surgery), along with directional changes in LV end-diastolic and end-
804 systolic volume (EDV and ESV) and LV ejection fraction (EF) over this time. **C**, Representative
805 trichrome stains of hearts from IL-4R α ^{ff} and IL-4R α ^{ff}LysM-Cre^{ERT2} sham and HF mice after 6 w
806 of tamoxifen (10 w post-surgery) along with fibrosis quantitation in the border and remote zone
807 (BZ and RZ). **D** and **E**, Representative flow plots for cardiac macrophages (F4/80⁺MerTK⁺),
808 CD206⁺ macrophages, and IL-4R α and IL-10R α expressing CD206⁺ subpopulations in IL-4R α ^{ff}

809 and IL-4R α^{ff} LysM-Cre^{ERT2} HF mice, along with quantitative group data from both sham and HF
810 male mice after 6 w of tamoxifen. **F**, Representative flow plots and quantitation of Ki67
811 expression in cardiac CD206⁺ and CD206⁻ macrophages from IL-4R α^{ff} and IL-4R α^{ff} LysM-
812 Cre^{ERT2} HF mice given tamoxifen for 6 w. Statistics: 2-way ANOVA with post-hoc Tukey's
813 multiple comparisons between groups in **B-E**; unpaired Student's t test in in **F**. N=7-11 per
814 group.

815 **Figure 6. *In vivo* IL-4R α silencing depletes cardiac CD206⁺ macrophages and**
816 **reverses LV remodeling in heart failure (HF). **A****, Protocol for treatment with IL-4R α antisense
817 oligonucleotides (ASOs) or mismatched (MM) control oligonucleotides (oligo) in HF mice from 4
818 to 8 w after non-reperfused myocardial infarction (MI) (sham controls). **B**, Representative long-
819 axis 2-dimensional echocardiograms at end-diastole from sham and HF mice treated with IL-
820 4R α ASOs or MM Oligos for 4 w (8 w post-surgery timepoint). Also shown are group data for LV
821 end-diastolic and end-systolic volume (EDV and ESV) and ejection fraction (EF) over the
822 treatment period. **C**, Gross images of hearts from IL-4R α ASO- and MM Oligo-treated sham and
823 HF mice, and group data for lung and heart weight (LW and HW) normalized to tibia length (TL).
824 **D**, Representative trichrome stains of IL-4R α ASO- and MM Oligo-treated sham and failing
825 hearts, and fibrosis quantitation in the border and remote zone (BZ and RZ). **E**, Representative
826 cardiac isolectin B4 (IB4, green) and WGA (red) staining and quantitation of myocyte cross-
827 sectional area and capillary:myocyte ratio in the LV RZ from IL-4R α ASO- and MM Oligo-treated
828 sham and HF mice. **F**, *Left*, quantitation of cardiac CD206⁺ macrophages, and *Middle and Right*,
829 flow plots and quantitation of IL-4R α and IL-10R α expressing subpopulations, in sham and HF
830 mice treated with IL-4R α ASOs or MM Oligos for 4 w. **G**, Serum levels of IL-4 and IL-10 from the
831 same groups. **H** and **I**, Representative flow cytometry histograms, dot plots, and quantitation of
832 cardiac Ki67⁺ (**H**) or bioparticle⁺ (**I**) CD206⁺ and CD206⁻ macrophages in IL-4R α ASO- and MM
833 Oligo- treated HF mice. Statistics: repeated-measures 1-way ANOVA with post-hoc Dunnett's

834 multiple comparison test for time series within groups in **B**; 2-way ANOVA with post-hoc Tukey's
835 multiple comparisons between groups in **B-F, H, I**; unpaired Student's t test in **G**. ** $p < 0.01$ vs.
836 respective Sham-MM Oligo; ## $p < 0.01$ vs. HF-MM Oligo at the same week post-surgery; $\Delta p < 0.05$,
837 $\Delta\Delta p < 0.01$ vs. respective 4 w timepoint. N=5-8 per group.

838 **Figure 7. Fizz1 is essential for CD206⁺ macrophage-induced myofibroblast**
839 **differentiation of cardiac mesenchymal stem cells (cMSCs).** **A**, cMSC-imbued collagen gel
840 contraction assays upon exposure to M[IL-4] bone marrow-derived macrophage (BMDM)
841 conditioned media or media alone control (Ctrl) containing isotype IgG or anti-Fizz1 antibody
842 with corresponding quantitation of gel areas. **B**, cMSC gel contraction assays upon exposure to
843 wild-type (WT) and Fizz1^{-/-} M0 or M[IL-4] BMDM conditioned media, and quantitation of gel
844 areas. N=3-5 per group for **A-B**. **C**, cMSC DLL-4 and Jagged1 gene expression after 30
845 minutes of treatment with either vehicle (Ctrl) or recombinant mouse (rm) Fizz1 50 ng/ml and
846 100 ng/ml. **D**, Immunoblotting and group quantitation for Notch1, Notch intracellular domain
847 (NICD), and α -smooth muscle actin (α -SMA) protein expression in cMSCs treated with either
848 vehicle Ctrl or rmFizz1 for 24 h following scrambled or Notch1 siRNA transfection. GAPDH
849 loading control. **E**, Representative low and high magnification confocal images of immunostains
850 for CD206 (red), IL-4R α (white) and Fizz1 (green) of hearts from sham and HF hearts (border
851 zone) from MM Oligo- or IL-4R α ASO-treated mice, with quantitation of CD206⁺IL-4R α ⁺Fizz1⁺
852 and CD206⁺IL-4R α ⁻Fizz1⁻ macrophages, and IL-4R α fluorescent intensity (arbitrary units [a.u.])
853 n=5-8/group. DAPI (blue) was used to label nuclei. Red arrows indicate CD206⁺IL-4R α ⁻Fizz1⁻
854 cells and yellow arrows indicate CD206⁺IL-4R α ⁺Fizz1⁺ cells. Statistics: 2-way ANOVA followed
855 by Tukey's multiple comparison test, except 1-way ANOVA followed by Tukey's multiple
856 comparison test in panel **C**; * $p < 0.05$, ** $p < 0.01$ vs. Ctrl in **C**; ** $p < 0.01$ vs. Ctrl-scramble siRNA,
857 ## $p < 0.01$ vs. rmFIZZ1-scramble siRNA in **D**. N=6 per group. MM, mismatched; ASO, antisense
858 oligonucleotide.

859 **Figure 8. Alternatively activated cardiac macrophages expand, express IL-4R α and**
860 **FIZZ3, and directly correlate with fibrosis in human heart failure (HF).** **A**, Representative
861 flow plots for CD45⁺Autofluorescence(Auto)⁺CD64⁺CD206⁺ macrophages and their CCR2
862 expression, and group quantitation for CD206⁺ macrophages in normal control (Ctrl; n=3) and
863 failing (n=13) human hearts (from LV assist device core tissue). **B**, Representative trichrome
864 stains (*Top*) and low and high magnification (immuno)stains for CD163 (red) and collagen-
865 hybridizing peptide (CHP, green) (*Bottom*) of Ctrl and failing human hearts, with corresponding
866 quantitation of cardiac fibrosis (10 Ctrl, 19 failing hearts) and CHP-associated and -
867 unassociated CD163⁺ macrophage frequency (n=7/group). **C**, Low and high magnification
868 confocal images of immunostains for CD163 (white), IL-4R α (red) and Fizz3 (green) in normal
869 (Ctrl; n=4) and failing (n=8) human hearts (HF), and quantitation of IL-4R α ⁺Fizz3⁺ and IL-
870 4R α ⁻Fizz3⁻ CD163⁺ macrophages. DAPI (blue) was used to label nuclei. White arrows indicate
871 CD163⁺IL-4R α ⁻Fizz3⁻ cells, and yellow arrows indicate CD163⁺IL-4R α ⁺Fizz3⁺ cells. Also shown
872 is the correlation between CD163⁺ macrophage abundance and LV fibrosis in human HF, n=19.
873 Statistics: Mann-Whitney test in **A**; unpaired Student's t test in **B-C**; Pearson R correlation test
874 in **C, lower right panel**.

875 **REFERENCES**

- 876 1. Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of
877 inflammation in heart failure. *Nat Rev Cardiol.* 2020;17:269-285. doi: 10.1038/s41569-
878 019-0315-x
- 879 2. Bajpai G, Schneider C, Wong N, Bredemeyer A, Hulsmans M, Nahrendorf M, Epelman S,
880 Kreisel D, Liu Y, Itoh A, et al. The human heart contains distinct macrophage subsets
881 with divergent origins and functions. *Nat Med.* 2018;24:1234-1245. doi: 10.1038/s41591-
882 018-0059-x
- 883 3. Heidt T, Courties G, Dutta P, Sager HB, Sebas M, Iwamoto Y, Sun Y, Da Silva N,
884 Panizzi P, van der Laan AM, et al. Differential contribution of monocytes to heart
885 macrophages in steady-state and after myocardial infarction. *Circ Res.* 2014;115:284-
886 295. doi: 10.1161/CIRCRESAHA.115.303567
- 887 4. Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD. Remodeling of the
888 mononuclear phagocyte network underlies chronic inflammation and disease
889 progression in heart failure: critical importance of the cardiosplenic axis. *Circ Res.*
890 2014;114:266-282. doi: 10.1161/CIRCRESAHA.113.301720
- 891 5. Sager HB, Hulsmans M, Lavine KJ, Moreira MB, Heidt T, Courties G, Sun Y, Iwamoto Y,
892 Tricot B, Khan OF, et al. Proliferation and Recruitment Contribute to Myocardial
893 Macrophage Expansion in Chronic Heart Failure. *Circ Res.* 2016;119:853-864. doi:
894 10.1161/CIRCRESAHA.116.309001
- 895 6. Dick SA, Macklin JA, Nejat S, Momen A, Clemente-Casares X, Althagafi MG, Chen J,
896 Kantores C, Hosseinzadeh S, Aronoff L, et al. Self-renewing resident cardiac
897 macrophages limit adverse remodeling following myocardial infarction. *Nat Immunol.*
898 2019;20:29-39. doi: 10.1038/s41590-018-0272-2
- 899 7. Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon B, Brija T, Gautier
900 EL, Ivanov S, Satpathy AT, et al. Embryonic and adult-derived resident cardiac
901 macrophages are maintained through distinct mechanisms at steady state and during
902 inflammation. *Immunity.* 2014;40:91-104. doi: 10.1016/j.immuni.2013.11.019
- 903 8. Lavine KJ, Epelman S, Uchida K, Weber KJ, Nichols CG, Schilling JD, Ornitz DM,
904 Randolph GJ, Mann DL. Distinct macrophage lineages contribute to disparate patterns
905 of cardiac recovery and remodeling in the neonatal and adult heart. *Proc Natl Acad Sci*
906 *U S A.* 2014;111:16029-16034. doi: 10.1073/pnas.1406508111
- 907 9. Bajpai G, Bredemeyer A, Li W, Zaitsev K, Koenig AL, Lokshina I, Mohan J, Ivey B, Hsiao
908 HM, Weinheimer C, et al. Tissue Resident CCR2- and CCR2+ Cardiac Macrophages
909 Differentially Orchestrate Monocyte Recruitment and Fate Specification Following
910 Myocardial Injury. *Circ Res.* 2019;124:263-278. doi: 10.1161/CIRCRESAHA.118.314028
- 911 10. Hilgendorf I, Gerhardt LM, Tan TC, Winter C, Holderried TA, Chousterman BG, Iwamoto
912 Y, Liao R, Zirlik A, Scherer-Crosbie M, et al. Ly-6Chigh monocytes depend on Nr4a1 to
913 balance both inflammatory and reparative phases in the infarcted myocardium. *Circ Res.*
914 2014;114:1611-1622. doi: 10.1161/CIRCRESAHA.114.303204
- 915 11. Prabhu SD, Frangogiannis NG. The Biological Basis for Cardiac Repair After Myocardial
916 Infarction: From Inflammation to Fibrosis. *Circ Res.* 2016;119:91-112. doi:
917 10.1161/CIRCRESAHA.116.303577
- 918 12. Prabhu SD. The Cardiosplenic Axis Is Essential for the Pathogenesis of Ischemic Heart
919 Failure. *Trans Am Clin Climatol Assoc.* 2018;129:202-214.
- 920 13. Revelo XS, Parthiban P, Chen C, Barrow F, Fredrickson G, Wang H, Yucel D, Herman A,
921 van Berlo JH. Cardiac Resident Macrophages Prevent Fibrosis and Stimulate
922 Angiogenesis. *Circ Res.* 2021;129:1086-1101. doi: 10.1161/CIRCRESAHA.121.319737
- 923 14. Martini E, Kunderfranco P, Peano C, Carullo P, Cremonesi M, Schorn T, Carriero R,
924 Termanini A, Colombo FS, Jachetti E, et al. Single-Cell Sequencing of Mouse Heart

- 925 Immune Infiltrate in Pressure Overload-Driven Heart Failure Reveals Extent of Immune
926 Activation. *Circulation*. 2019;140:2089-2107. doi:
927 10.1161/CIRCULATIONAHA.119.041694
- 928 15. Shiraishi M, Shintani Y, Shintani Y, Ishida H, Saba R, Yamaguchi A, Adachi H, Yashiro
929 K, Suzuki K. Alternatively activated macrophages determine repair of the infarcted adult
930 murine heart. *J Clin Invest*. 2016;126:2151-2166. doi: 10.1172/JCI85782
- 931 16. Yan X, Anzai A, Katsumata Y, Matsuhashi T, Ito K, Endo J, Yamamoto T, Takeshima A,
932 Shinmura K, Shen W, et al. Temporal dynamics of cardiac immune cell accumulation
933 following acute myocardial infarction. *J Mol Cell Cardiol*. 2013;62:24-35. doi:
934 10.1016/j.yjmcc.2013.04.023
- 935 17. Leblond AL, Klinkert K, Martin K, Turner EC, Kumar AH, Browne T, Caplice NM.
936 Systemic and Cardiac Depletion of M2 Macrophage through CSF-1R Signaling Inhibition
937 Alters Cardiac Function Post Myocardial Infarction. *PLoS One*. 2015;10:e0137515. doi:
938 10.1371/journal.pone.0137515
- 939 18. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and
940 functions. *Immunity*. 2010;32:593-604. doi: 10.1016/j.immuni.2010.05.007
- 941 19. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for
942 reassessment. *F1000Prime Rep*. 2014;6:13. doi: 10.12703/P6-13
- 943 20. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton
944 JA, Ivashkiv LB, Lawrence T, et al. Macrophage activation and polarization:
945 nomenclature and experimental guidelines. *Immunity*. 2014;41:14-20. doi:
946 10.1016/j.immuni.2014.06.008
- 947 21. Wynn TA, Vannella KM. Macrophages in Tissue Repair, Regeneration, and Fibrosis.
948 *Immunity*. 2016;44:450-462. doi: 10.1016/j.immuni.2016.02.015
- 949 22. Tugal D, Liao X, Jain MK. Transcriptional control of macrophage polarization.
950 *Arterioscler Thromb Vasc Biol*. 2013;33:1135-1144. doi: 10.1161/ATVBAHA.113.301453
- 951 23. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system
952 in diverse forms of macrophage activation and polarization. *Trends Immunol*.
953 2004;25:677-686. doi: 10.1016/j.it.2004.09.015
- 954 24. Shintani Y, Ito T, Fields L, Shiraishi M, Ichihara Y, Sato N, Podaru M, Kainuma S,
955 Tanaka H, Suzuki K. IL-4 as a Repurposed Biological Drug for Myocardial Infarction
956 through Augmentation of Reparative Cardiac Macrophages: Proof-of-Concept Data in
957 Mice. *Sci Rep*. 2017;7:6877. doi: 10.1038/s41598-017-07328-z
- 958 25. Tang PM, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal
959 inflammation and fibrosis. *Nat Rev Nephrol*. 2019;15:144-158. doi: 10.1038/s41581-019-
960 0110-2
- 961 26. Bansal SS, Ismahil MA, Goel M, Patel B, Hamid T, Rokosh G, Prabhu SD. Activated T
962 Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure.
963 *Circ Heart Fail*. 2017;10:e003688. doi: 10.1161/CIRCHEARTFAILURE.116.003688
- 964 27. Herbert DR, Holscher C, Mohrs M, Arendse B, Schwegmann A, Radwanska M, Leeto M,
965 Kirsch R, Hall P, Mossmann H, et al. Alternative macrophage activation is essential for
966 survival during schistosomiasis and downmodulates T helper 1 responses and
967 immunopathology. *Immunity*. 2004;20:623-635. doi: 10.1016/s1074-7613(04)00107-4
- 968 28. Vishlaghi N, Guo L, Griswold-Wheeler D, Sun Y, Booker C, Crossley JL, Bancroft AC,
969 Juan C, Korlakunta S, Ramesh S, et al. Vegfc-expressing cells form heterotopic bone
970 after musculoskeletal injury. *Cell Rep*. 2024;43:114049. doi:
971 10.1016/j.celrep.2024.114049
- 972 29. Bansal SS, Ismahil MA, Goel M, Zhou G, Rokosh G, Hamid T, Prabhu SD. Dysfunctional
973 and Proinflammatory Regulatory T-Lymphocytes Are Essential for Adverse Cardiac
974 Remodeling in Ischemic Cardiomyopathy. *Circulation*. 2019;139:206-221. doi:
975 10.1161/CIRCULATIONAHA.118.036065

- 976 30. Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, Prabhu SD. Divergent
977 tumor necrosis factor receptor-related remodeling responses in heart failure: role of
978 nuclear factor-kappaB and inflammatory activation. *Circulation*. 2009;119:1386-1397. doi:
979 10.1161/CIRCULATIONAHA.108.802918
- 980 31. Wang G, Hamid T, Keith RJ, Zhou G, Partridge CR, Xiang X, Kingery JR, Lewis RK, Li Q,
981 Rokosh DG, et al. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the
982 failing heart. *Circulation*. 2010;121:1912-1925. doi:
983 10.1161/CIRCULATIONAHA.109.905471
- 984 32. Patel B, Bansal SS, Ismahil MA, Hamid T, Rokosh G, Mack M, Prabhu SD. CCR2(+)
985 Monocyte-Derived Infiltrating Macrophages Are Required for Adverse Cardiac
986 Remodeling During Pressure Overload. *JACC Basic Transl Sci*. 2018;3:230-244. doi:
987 10.1016/j.jacbts.2017.12.006
- 988 33. Hamid T, Xu Y, Ismahil MA, Rokosh G, Jinno M, Zhou G, Wang Q, Prabhu SD. Cardiac
989 Mesenchymal Stem Cells Promote Fibrosis and Remodeling in Heart Failure: Role of
990 PDGF Signaling. *JACC Basic Transl Sci*. 2022;7:465-483. doi:
991 10.1016/j.jacbts.2022.01.004
- 992 34. Wang Q, Wang S, Sun Z. Kidney-Specific Klotho Gene Deletion Causes Aortic
993 Aneurysm via Hyperphosphatemia. *Hypertension*. 2021;78:308-319. doi:
994 10.1161/HYPERTENSIONAHA.121.17299
- 995 35. Tang L, Zhang H, Wang C, Li H, Zhang Q, Bai J. M2A and M2C Macrophage Subsets
996 Ameliorate Inflammation and Fibroproliferation in Acute Lung Injury Through Interleukin
997 10 Pathway. *Shock*. 2017;48:119-129. doi: 10.1097/SHK.0000000000000820
- 998 36. Hamid T, Xu Y, Ismahil MA, Li Q, Jones SP, Bhatnagar A, Bolli R, Prabhu SD. TNF
999 receptor signaling inhibits cardiomyogenic differentiation of cardiac stem cells and
1000 promotes a neuroadrenergic-like fate. *Am J Physiol Heart Circ Physiol*. 2016;311:H1189-
1001 H1201. doi: 10.1152/ajpheart.00904.2015
- 1002 37. Bujak M, Ratkaj I, Markova-Car E, Jurisic D, Horvatic A, Vucinic S, Lerga J, Baus-Loncar
1003 M, Pavelic K, Kraljevic Pavelic S. Inflammatory Gene Expression Upon TGF-beta1-
1004 Induced p38 Activation in Primary Dupuytren's Disease Fibroblasts. *Front Mol Biosci*.
1005 2015;2:68. doi: 10.3389/fmolb.2015.00068
- 1006 38. Covarrubias R, Ismahil MA, Rokosh G, Hamid T, Accornero F, Singh H, Gumina RJ,
1007 Prabhu SD, Bansal SS. Optimized protocols for isolation, fixation, and flow cytometric
1008 characterization of leukocytes in ischemic hearts. *Am J Physiol Heart Circ Physiol*.
1009 2019;317:H658-H666. doi: 10.1152/ajpheart.00137.2019
- 1010 39. Trouplin V, Boucherit N, Gorvel L, Conti F, Mottola G, Ghigo E. Bone marrow-derived
1011 macrophage production. *J Vis Exp*. 2013:e50966. doi: 10.3791/50966
- 1012 40. Ripple MJ, You D, Honnegowda S, Giaimo JD, Sewell AB, Becnel DM, Cormier SA.
1013 Immunomodulation with IL-4R alpha antisense oligonucleotide prevents respiratory
1014 syncytial virus-mediated pulmonary disease. *J Immunol*. 2010;185:4804-4811. doi:
1015 10.4049/jimmunol.1000484
- 1016 41. Weng SY, Wang X, Vijayan S, Tang Y, Kim YO, Padberg K, Regen T, Molokanova O,
1017 Chen T, Bopp T, et al. IL-4 Receptor Alpha Signaling through Macrophages Differentially
1018 Regulates Liver Fibrosis Progression and Reversal. *EBioMedicine*. 2018;29:92-103. doi:
1019 10.1016/j.ebiom.2018.01.028
- 1020 42. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, Libby
1021 P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two
1022 monocyte subsets with divergent and complementary functions. *J Exp Med*.
1023 2007;204:3037-3047. doi: 10.1084/jem.20070885
- 1024 43. Bakhshian Nik A, Alvarez-Argote S, O'Meara CC. Interleukin 4/13 signaling in cardiac
1025 regeneration and repair. *Am J Physiol Heart Circ Physiol*. 2022;323:H833-H844. doi:
1026 10.1152/ajpheart.00310.2022

- 1027 44. Shankar A, McAlees JW, Lewkowich IP. Modulation of IL-4/IL-13 cytokine signaling in
1028 the context of allergic disease. *J Allergy Clin Immunol.* 2022;150:266-276. doi:
1029 10.1016/j.jaci.2022.06.012
- 1030 45. Junntila IS. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13
1031 Receptor Complexes. *Front Immunol.* 2018;9:888. doi: 10.3389/fimmu.2018.00888
- 1032 46. Krawiec P, Pawlowska-Kamieniak A, Pac-Kozuchowska E. Interleukin 10 and interleukin
1033 10 receptor in paediatric inflammatory bowel disease: from bench to bedside lesson. *J*
1034 *Inflamm (Lond).* 2021;18:13. doi: 10.1186/s12950-021-00279-3
- 1035 47. Walter MR. The molecular basis of IL-10 function: from receptor structure to the onset of
1036 signaling. *Curr Top Microbiol Immunol.* 2014;380:191-212. doi: 10.1007/978-3-662-
1037 43492-5_9
- 1038 48. Jones B, Debski A, Hans CP, Go MR, Agarwal G. Structurally abnormal collagen fibrils
1039 in abdominal aortic aneurysm resist platelet adhesion. *J Thromb Haemost.* 2022;20:470-
1040 477. doi: 10.1111/jth.15576
- 1041 49. Cao Q, Wang Y, Zheng D, Sun Y, Wang Y, Lee VW, Zheng G, Tan TK, Ince J,
1042 Alexander SI, et al. IL-10/TGF-beta-modified macrophages induce regulatory T cells and
1043 protect against adriamycin nephrosis. *J Am Soc Nephrol.* 2010;21:933-942. doi:
1044 10.1681/ASN.2009060592
- 1045 50. Roszer T. Understanding the Mysterious M2 Macrophage through Activation Markers
1046 and Effector Mechanisms. *Mediators Inflamm.* 2015;2015:816460. doi:
1047 10.1155/2015/816460
- 1048 51. Nair MG, Du Y, Perrigoue JG, Zaph C, Taylor JJ, Goldschmidt M, Swain GP,
1049 Yancopoulos GD, Valenzuela DM, Murphy A, et al. Alternatively activated macrophage-
1050 derived RELM- α is a negative regulator of type 2 inflammation in the lung. *J Exp*
1051 *Med.* 2009;206:937-952. doi: 10.1084/jem.20082048
- 1052 52. Nair MG, Gallagher IJ, Taylor MD, Loke P, Coulson PS, Wilson RA, Maizels RM, Allen
1053 JE. Chitinase and Fizz family members are a generalized feature of nematode infection
1054 with selective upregulation of Ym1 and Fizz1 by antigen-presenting cells. *Infect Immun.*
1055 2005;73:385-394. doi: 10.1128/IAI.73.1.385-394.2005
- 1056 53. Liu T, Hu B, Choi YY, Chung M, Ullenbruch M, Yu H, Lowe JB, Phan SH. Notch1
1057 signaling in FIZZ1 induction of myofibroblast differentiation. *Am J Pathol.*
1058 2009;174:1745-1755. doi: 10.2353/ajpath.2009.080618
- 1059 54. Liu T, Yu H, Ullenbruch M, Jin H, Ito T, Wu Z, Liu J, Phan SH. The in vivo fibrotic role of
1060 FIZZ1 in pulmonary fibrosis. *PLoS One.* 2014;9:e88362. doi:
1061 10.1371/journal.pone.0088362
- 1062 55. Jenkins SJ, Ruckerl D, Thomas GD, Hewitson JP, Duncan S, Brombacher F, Maizels
1063 RM, Hume DA, Allen JE. IL-4 directly signals tissue-resident macrophages to proliferate
1064 beyond homeostatic levels controlled by CSF-1. *J Exp Med.* 2013;210:2477-2491. doi:
1065 10.1084/jem.20121999
- 1066 56. Rizzo P, Miele L, Ferrari R. The Notch pathway: a crossroad between the life and death
1067 of the endothelium. *Eur Heart J.* 2013;34:2504-2509. doi: 10.1093/eurheartj/ehs141
- 1068 57. Talele NP, Fradette J, Davies JE, Kapus A, Hinz B. Expression of alpha-Smooth Muscle
1069 Actin Determines the Fate of Mesenchymal Stromal Cells. *Stem Cell Reports.*
1070 2015;4:1016-1030. doi: 10.1016/j.stemcr.2015.05.004
- 1071 58. Lurier EB, Dalton D, Dampier W, Raman P, Nassiri S, Ferraro NM, Rajagopalan R,
1072 Sarmady M, Spiller KL. Transcriptome analysis of IL-10-stimulated (M2c) macrophages
1073 by next-generation sequencing. *Immunobiology.* 2017;222:847-856. doi:
1074 10.1016/j.imbio.2017.02.006
- 1075 59. Pine GM, Batugedara HM, Nair MG. Here, there and everywhere: Resistin-like
1076 molecules in infection, inflammation, and metabolic disorders. *Cytokine.* 2018;110:442-
1077 451. doi: 10.1016/j.cyto.2018.05.014

- 1078 60. Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and
1079 therapeutic aspects. *Antioxid Redox Signal*. 2013;18:2352-2363. doi:
1080 10.1089/ars.2012.4834
- 1081 61. Frangogiannis NG. Cardiac fibrosis. *Cardiovasc Res*. 2021;117:1450-1488. doi:
1082 10.1093/cvr/cvaa324
- 1083 62. Pechkovsky DV, Prasse A, Kollert F, Engel KM, Dentler J, Luttmann W, Friedrich K,
1084 Muller-Quernheim J, Zissel G. Alternatively activated alveolar macrophages in
1085 pulmonary fibrosis-mediator production and intracellular signal transduction. *Clin*
1086 *Immunol*. 2010;137:89-101. doi: 10.1016/j.clim.2010.06.017
- 1087 63. Wang J, Xu L, Xiang Z, Ren Y, Zheng X, Zhao Q, Zhou Q, Zhou Y, Xu L, Wang Y.
1088 Microcystin-LR ameliorates pulmonary fibrosis via modulating CD206(+) M2-like
1089 macrophage polarization. *Cell Death Dis*. 2020;11:136. doi: 10.1038/s41419-020-2329-z
- 1090 64. Carlson S, Helterline D, Asbe L, Dupras S, Minami E, Farris S, Stempien-Otero A.
1091 Cardiac macrophages adopt profibrotic/M2 phenotype in infarcted hearts: Role of
1092 urokinase plasminogen activator. *J Mol Cell Cardiol*. 2017;108:42-49. doi:
1093 10.1016/j.yjmcc.2016.05.016
- 1094 65. Sieweke MH, Allen JE. Beyond stem cells: self-renewal of differentiated macrophages.
1095 *Science*. 2013;342:1242974. doi: 10.1126/science.1242974
- 1096 66. Martinez FO, Helming L, Milde R, Varin A, Melgert BN, Draijer C, Thomas B, Fabbri M,
1097 Crawshaw A, Ho LP, et al. Genetic programs expressed in resting and IL-4 alternatively
1098 activated mouse and human macrophages: similarities and differences. *Blood*.
1099 2013;121:e57-69. doi: 10.1182/blood-2012-06-436212
- 1100 67. Kim JE, Jung K, Kim JA, Kim SH, Park HS, Kim YS. Engineering of anti-human
1101 interleukin-4 receptor alpha antibodies with potent antagonistic activity. *Sci Rep*.
1102 2019;9:7772. doi: 10.1038/s41598-019-44253-9
- 1103 68. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman
1104 HB, Wright BD, Skelton NJ, et al. FIZZ1, a novel cysteine-rich secreted protein
1105 associated with pulmonary inflammation, defines a new gene family. *EMBO J*.
1106 2000;19:4046-4055. doi: 10.1093/emboj/19.15.4046
- 1107 69. Chemaly ER, Hadri L, Zhang S, Kim M, Kohlbrenner E, Sheng J, Liang L, Chen J, P KR,
1108 Hajjar RJ, et al. Long-term in vivo resistin overexpression induces myocardial
1109 dysfunction and remodeling in rats. *J Mol Cell Cardiol*. 2011;51:144-155. doi:
1110 10.1016/j.yjmcc.2011.04.006
- 1111 70. Takeishi Y, Niizeki T, Arimoto T, Nozaki N, Hirono O, Nitobe J, Watanabe T, Takabatake
1112 N, Kubota I. Serum resistin is associated with high risk in patients with congestive heart
1113 failure--a novel link between metabolic signals and heart failure. *Circ J*. 2007;71:460-464.
1114 doi: 10.1253/circj.71.460
1115




Figure 1




Figure 2







Figure 3






Figure 5




Figure 6




Figure 7





Figure 8